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1.1
FUNCTIONAL ANALYSIS OF THE CANDIDATE BLADDER
TUMOUR SUPPRESSOR, DBCCR1 JH Gill*, E Pitt, H Nishiyama, 
N Hornigold, MA Knowles, ICRF Clinical Centre, St James University
Hospital, Leeds, LS9 7TF, UK 
Genomic alterations of chromosome 9q, particularly deletions, are the most common
genetic alteration in all stages and grades of bladder cancer. DBCCR1 is the only
candidate tumour suppressor gene so far identified within the gene-poor critical
region of deletion at 9q32–33. Previously, this gene was shown to be silenced by
promoter hypermethylation in 50% of bladder cancer cell lines and be homozygously
deleted in primary tumours, but small intragenic tumour-specific mutations have not
been identified. Exogenous expression of DBCCR1 protein resulted in suppression of
proliferation in NIH/3T3 cells, due to an accumulation of cells within G1 of the cell
cycle, further supporting the hypothesis that DBCCR1 is a tumour suppressor gene.
Here we sought to further these observations, and to provide a role for DBCCR1 in the
bladder. Expression of DBCCR1 in bladder cancer cell lines resulted in in vitro
growth inhibition, reduced in vitro colony formation and soft agar clonogenicity and 
a suppression of tumorigenicity in an in vivo mouse model. Furthermore, since
DBCCR1 shows no homology to any known protein, the presence of functional
protein domains within DBCCR1 was also investigated. DBCCR1 was found to be
located primarily cytoplasmically and to contain three main functional regions. The
involvement of these regions is currently under investigation. Taken together these
observations reinforce a role for DBCCR1 in growth control, and support the
hypothesis that this is the tumour suppressor gene targeted by 9q32–33 deletion in
bladder cancer. 
1.2
INTERLEUKIN-10 GENE POLYMORPHISMS INFLUENCE
TUMOUR DEVELOPMENT IN CUTANEOUS MALIGNANT
MELANOMA WM Howell1, SJ Turner1, AC Bateman2, JM Theaker2, 1Human
Genetics, University of Southampton, 2Department of Histopathology,
Southampton University Hospitals, Southampton SO16 6YD, UK 
Cutaneous malignant melanoma (CMM) is a serious and often fatal malignancy, in
which patients may develop an anti-tumour immune response. Conflicting evidence
suggests that IL-10 contributes to tumour escape from the immune response, but can
also have an anti-tumour effect, via inhibition of angiogenesis. To distinguish between
these models and to determine whether genotypes associated with differential IL-10
expression confer susceptibility to and/or influence prognosis in CMM, 153 British
caucasian CMM patients and 158 controls were genotyped for IL-10 promoter SNPs
by ARMS-PCR. The IL-10 -1082 AA low expression genotype was increased in inci-
dence among CMM patients (26.8% vs 17.1%; P = 0.04; OR = 1.8 (95% CI 1.0–3.1)).
In addition, IL-10 genotypes showed significant associations with three of four prog-
nostic indicators examined:-IL-10 -1082 GG and -1082, -819 and -592 GCC/GCC
compound high expression genotypes were associated with horizontal (non-invasive)
vs vertical (invasive) tumour growth (38.3% vs 20.4%; P = 0.02; OR = 2.4 (0.4–1.0)
and 37.8% vs 20.8%; P = 0.03; OR = 2.3 (1.1–5.0) respectively); the IL-10 -1082 AA
low expression genotype was associated with more advanced (Stage II–IV vs Stage I)
disease (34.5% vs 19.0%; P = 0.04; OR = 2.2 (1.0–4.8)); Finally, the IL-10 -1082 AA
and -1082, -819 and -592 ACC/ACC, ACC/ATA and ATA/ATA compound low
expression genotypes were significantly increased in frequency among patients with
thicker (> 1.5 mm) primary vertical growth phase tumours (20/50 (40.0%)) vs 8/52
(15.4%); P = 0.005; OR = 3.7 (1.4–9.4) and 18/47 (38.3%) vs 7/48 (14.6%); 
P = 0.009; OR = 3.6 (1.4–9.8) respectively). Also, tumour thickness was significantly
greater among patients with low IL-10 vs high IL-10 expression genotypes (2.72 mm
± 3.32 vs 1.16 mm ± 1.11; P = 0.002). 
These results indicate that genotypes associated with high levels of IL-10 expres-
sion in vitro are protective in CMM, while low expression genotypes are a risk factor
for more advanced/poorer prognosis disease and may confer susceptibility to CMM.
Although the influence of IL-10 on melanoma development is likely to be complex,
these results support recent findings that IL-10 has an anti-tumour effect in CMM,
possibly via inhibition of angiogenesis. These findings may have implications for
tumour immunotherapy. 
1.3
THE INHIBITOR OF APOPTOSIS GENE SURVIVIN IS
UPREGULATED IN OESOPHAGEAL CANCER DM Beardsmore, 
C Verbeke, AI Sarela, AGK Li, CL Davies, PJ Guillou, GWB Clark, Academic
Department of Surgery and Histopathology, St James’s University Hospital,
Leeds, LS9 7TF, UK 
Background Survivin is a recently described Inhibitor of Apoptosis gene and its
expression in cancer has been shown to alter tumour behaviour. Consequently,
Survivin has been proposed as a potential therapeutic target and prognostic molecular
marker. We aimed to investigate the expression of Survivin mRNA and protein in
oesophageal tumours. 
Methods Survivin mRNA was evaluated by RT-PCR on RNA extracted from 68
snap frozen oesophageal tumours and matched normal oesophageal mucosa. The
Survivin PCR products were semi-quantitatively scored (0–4) after standardising with
the expression of the control gene, G3PDH. Tissue was sampled from 41 resection
specimens and 27 endoscopic biopsies comprising 56 (82%) adenocarcinomas [Type
1 = 32 (57%), Type 2 = 12 (21.5%) and Type 3 = 12 (21.5%)], 10 (15%) squamous cell
cancers and 2 (3%) of mixed histology. 55% of tumours were poorly differentiated,
38% moderately differentiated and 7% well differentiated. Resection specimens were
staged T1 = 5 (12%), T2 = 9 (22%), T3 = 27 (66%) and 30 were positive for nodal
metastases. Immunohistochemistry was performed on a subset of 28 tumours using
the polyclonal antibody SURV11A. Immunostaining was categorized by the
percentage of tumour cells immunostained (0 = <5%, 1 = 5–25%, 2 = 26–50%, 3 =
51–75%, 4 = >75%) and the intensity of staining (1+, 2+ and 3+) and a Weighted
Index (WI) was calculated. 
Results By RT-PCR, 64 (94%) of oesophageal cancers and 53 (78%) of normal
oesophageal mucosa samples were positive for mRNA expression. Using semi-
quantitative scoring 37 (54%) of tumours showed upregulation of Survivin mRNA
expression 27 (40%) similar expression and 4 (6%) relatively reduced expression
compared to matched normal controls. Up-regulation of Survivin did not correlate
with the clinicopathological variables of tumour histology, stage, differentiation, pres-
ence of nodal metastases, age and sex. The WI score revealed heterogenous protein
expression for Survivin between the tumours with 13 (46%) showing relatively high
levels of immunostaining (WI > 9), 7 (25%) moderate staining (WI 4–8) and 8 (29%)
weak staining (WI < 4). In addition normal oesophageal mucosa stained positively
and this was restricted to the basal layer of the mucosa. 
Conclusion Survivin mRNA appears to be constitutively expressed at low levels in
normal oesophageal mucosa and oesophageal cancer. However, 54% of these tumours
show significant upregulation of Survivin mRNA expression. Survivin protein was
also detected in these tumours using immunohistochemistry. There was considerable
variability in the degree of staining between tumours and this differential expression
of Survivin may potentially alter response to treatment. 
1.4
THE NUCLEAR DEAD BOX PROTEIN P68 IS OVER-EXPRESSED
AND POST-TRANSLATIONALLY MODIFIED IN COLORECTAL
TUMOURS RG Hislop, M Causevic, NM Kernohan, FC Carey, F Fuller-Pace,
Dept of Molecular and Cellular Pathology, University of Dundee, Ninewells
Medical School, Dundee, DD1 9TS, UK 
The nuclear protein p68 is a prototypic member of a family of RNA helicases
containing eight conserved motifs including the DEAD box (Asp-Glu-Ala-Asp). p68
expression is growth and developmentally regulated and appears to correlate with
organ differentiation/maturation in the foetus. As other members of the DEAD box
family are known to be over-expressed in tumour cell lines, we have compared p68
expression in normal colon, colorectal adenoma and colorectal carcinoma tissue. 
Immunohistochemical staining of colon tissue sections showed increased levels of
p68 in cancers compared to matched normal colon from the same patient. Western
blotting also indicated a higher level of p68 expression in tumour tissue but while a
single band was detected in most normal tissue extracts, p68 migrated as multiple
forms with lower electrophoretic mobility in tumour tissue. The normal band was of
lower intensity or completely absent in tumour tissue. These results were consistent
among a preliminary sample of 20 patients. We observed no obvious over-expression
of p68 at the RNA level. Transfection of cell lines with p68 and ubiquitin expression
plasmids has shown that this phenomenon can be reproduced in tissue culture cells
and provides a model for further detailed studies. 
The results of this study suggest that there is an increase in the level of p68 in pre-
invasive and invasive colorectal tumours. It is possible that accumulation of p68
occurs due to a fault in degradation of ubiquitinated proteins. We are currently inves-
tigating by RT-PCR whether there are underlying mutations in the p68 gene. 
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1.5
GENETIC ANALYSIS OF GASTRO-OESOPHAGEAL MALIGNANCY
BY CGH SC Stocks1,2, FA Carey2, AM Thompson3, D Johnston3, 
NM Kernohan2, NR Pratt2, Departments of 1Human Genetics, 2Molecular and
Cellular Pathology and 3Surgery, Ninewells Hospital and Medical School,
Dundee DD1 9SY, UK 
Gastro-oesophageal cancers are common throughout the world but because of late
presentation are associated with a poor prognosis. World-wide, squamous cell carci-
nomas (SCC) are by far the most common form of oesophageal malignancy. However,
in the West there has been a remarkable change in the epidemiology such that the UK
rate of gastro-oesophageal adenocarcinoma (GOA) is among the highest in the world.
We have used comparative genomic hybridisation (CGH) to investigate patterns of
large scale genetic change in a series of approximately 100 gastro-oesophageal
cancers. This unselected study has revealed distinct patterns of genetic change (gain
and loss) in SCC and GOA. Both tumour types showed frequent gain of 3q, 5p, 8q,
20q and loss of 18q. However, SCC showed specific amplification of 11q13 (cyclin
D1) loss of 3p but seldom had whole arm gains of 13q or loss of 17p (p53) whereas
GOA had frequent gains of 13q and loss of 17p but rarely exhibited 3p deletion or
11q13 gain. The identification of consistent regions of abnormality for each tumour
type implicates the effects of clonal karyotypic abnormalities in the pathogenesis of
each type of malignancy. Furthermore, this study emphasises a role for CGH and
related whole genome analysis techniques in characterising distinct tumour subtypes. 
1.6
MORPHOMETRIC ANALYSIS OF HEAT SHOCK PROTEIN 27
EXPRESSION; A NOVEL MARKER OF INCREASED BREAST
CANCER RISK A Shaaban†1, P O’Neill2, A Dodson1, CS Foster1,
1Department of Cellular and Molecular Pathology, Royal Liverpool University
Hospital, Liverpool, 2Clatterbridge Centre for Oncology, Merseyside, UK 
Heat shock proteins (hsps) are molecular chaperones that are induced in cells in
response to different stimuli. In previous studies, hsp27 overexpression was found to
correlate with poor prognosis in breast carcinomas. However, its role in precancerous
breast lesions has not yet been determined. Dysregulation of its expression in pre-
cancerous breast lesions may represent an early step in mammary oncogenesis.
Therefore, we conducted a case-control study on paraffin embedded biopsy specimens
from patients who subsequently developed breast cancer (cases, n = 120) against
controls, age and date of biopsy matched, (n = 382) who did not develop breast cancer
spanning a twenty year follow-up period. Foci of hyperplasia of thr usual type (HUT)
were identified in tissues and the relative risk of HUT was defined. Tissue sections
containing foci of HUT (n = 162) and surrounding normal lobules (n = 93) from cases
(n = 28) and controls (n = 21) were stained using a monoclonal antibody (Novocastra
Laboratories Ltd.) for hsp27 with heat pretreatment for antigen unmasking. The
percentage of positive cells was assessed and the mean area and optical density (OD)
of positive staining in hyperplastic and normal foci were quantified using morpho-
metric image analysis. The mean expression in HUT (±SD) was 29.32% (29.45) in
biopsies from patients who subsequently developed breast cancer compared with
13.92% (18.67) in controls. This difference was highly significant (P < 0.001).Among
cases subsequently developing breast cancer, a significant overexpression of hsp27
was found in HUT foci compared with normal lobules (P < 0.0001). In HUT , there
was a strong positive correlation between mean hsp27 expression and densitometry
(OD) (r = 0.836, P < 0.0001). The latter was higher in cases compared with controls.
The mean HUT OD (±SD) was 0.49 (0.21) in cases developing breast cancer and 0.43
(0.25) in controls while normal foci showed OD of 0.42 (0.21) and 0.32 (0.23) in cases
and controls respectively. Using a cut-off point for hut OD of 0.45, a significant differ-
ence was found between cases and controls (P < 0.024). These data suggest a previ-
ously undefined role of hsp27 during mammary carcinogenesis and indicate that the
overexpression of hsp27 may define a subnet of hyperplastic breast lesions, which are
phenotypically benign but biologically aggressive. This might have important impli-
cations for the improvement of screening and management regimens.
1.7
POLYMORPHISM IN GST P1 ASSOCIATED WITH RISK OF
ACUTE MYELOID LEUKAEMIA FOLLOWING CHEMOTHERAPY
JM Allan1, CP Wild1, S Rollinson2, EV Willett1, GJ Dovey2, A Moorman1, 
E Roman1, RA Cartwright1 and GJ Morgan2, 1Epidemiology and HSR and
2Department of Haematology, School of Medicine, University of Leeds
Glutathione  S-transferases (GSTs) detoxify potentially mutagenic and cytotoxic
DNA-reactive electrophiles by conjugation to glutathione. In addition to protecting
against endogenously-formed and environmentally-derived electrophiles, GSTs, and
particularly GST P1, also protect against the cytotoxic effects of several chemothera-
peutic agents. Ironically, these agents, which include cyclophosphamide, etoposide,
adriamycin and cisplatin derivatives, are also suspect human mutagens and carcino-
gens, and therefore may confer a risk of cancer. Polymorphisms of functional signifi-
cance exist in at least 3 genes encoding GSTs, including GST M1, GST T1 and GST
P1. We hypothesise therefore, that polymorphisms in these genes alter susceptibility
to chemotherapy-induced carcinogenesis. Therapy-related acute myeloid leukaemia
(t-AML) is a devastating complication of long-term cancer survival. Identification of
genetic determinants may help to identify individuals at increased risk of developing
t-AML. To this end, we have examined 89 cases of t-AML for the frequency of poly-
morphisms in GST T1, GST M1 and GST P1, and compared this to the frequency in a
matched control population. Gene deletion of GST T1 was associated with suscepti-
bility to t-AML in males (OR 2.61, 95% CI 1.11–6.09) but not in females (OR 1.06,
95% CI 0.46–2.47). Gene deletion of GST M1 was not significantly associated with
susceptibility to t-AML. Individuals with the GST P1 codon 105 valine allele were
significantly over-represented in cases compared to their matched controls, suggesting
an increased risk of developing t-AML [Odds Ratio (OR) 2.26, 95% Confidence
Interval (CI) 1.38–3.71, 89 cases, 259 controls]. Moreover, a significantly increased
risk of t-AML for individuals with codon 105 valine was only seen in those with prior
exposure to chemotherapy (OR 4.00, 95% CI 1.95–8.21, 51 cases, 150 controls), and
particularly with prior exposure to a known GST P1 substrate (OR 6.56, 95% CI
2.11–20.43, 22 cases, 64 controls). GST P1 codon 105 status was not associated with
risk of t-AML in those individuals with prior exposure to radiotherapy alone (OR
1.18, 95% CI 0.57–2.44, 38 cases, 109 controls). Thus, inheritance of at least one
valine allele at GST P1 codon 105 confers a significantly increased risk of developing
t-AML following cytotoxic chemotherapy, but not radiotherapy. This work was
supported by the Kay Kendall Leukaemia Research Fund and the Leukaemia
Research Fund. 
1.8
PROTEOMIC IDENTIFICATION OF DIFFERENTIALLY
EXPRESSED PROTEINS IN RENAL CELL CARCINOMA 
RD Unwin1, R Craven1, P Harnden1, DJ Pappin2, N Totty2, PJ Selby1, 
RE Banks1, 1ICRF Cancer Medicine Research Unit, St. James University
Hospital, Leeds, LS9 7TF, 2ICRF Protein Sequencing Laboratory, 44 Lincolns
Inn Fields, London, WC2A 3PX, UK 
Renal cell carcinoma (RCC) is the tenth most common cancer worldwide and is
responsible for around 5% of all cancer deaths. Approximately half of all RCC
patients are diagnosed with advanced disease, with 5-year survival for rates of about
20%. 
In order to identify potentially novel markers or drug targets for RCC, we have
used two-dimensional gel electrophoresis and mass spectrometry to identify proteins
that are differentially expressed by clear cell renal tumours when compared to normal
kidney. 
The protein profiles of matched tumour and normal tissues from 6 patients with
grade 3 clear cell RCC were studied. Computer analysis revealed a total of 73 poten-
tial differentially expressed proteins, 32 of which are upregulated in 4/6 and 41 that
appear to be downregulated in 6/6 RCCs. Proteins were identified by peptide mass
fingerprinting and MALDI mass spectrometry. Some of the proteins identified have
previously been shown to be overexpressed in RCC including pyruvate kinase and
Mn-superoxide dismutase whilst some proteins have not previously been linked to
tumorigenesis, such as annexin II, lamin B1 and cofilin. 
A number of proteins identified by this screen are currently being further charac-
terised using RT-PCR, tandem mass spectrometry and immunohistochemistry to
ascertain their potential role in either disease pathogenesis or as potential disease
markers. 14 Oral presentations
2.1
DEVELOPMENT OF MOLECULAR IMAGING PARADIGMS 
EO Aboagye, CRC PET Oncology group, Department of Cancer
Medicine, Imperial College School of Medicine, Du Cane Road, London 
W12 0NN, UK 
Imaging probes and paradigms can be used to enhance the scientific impact of cancer
trials. This abstract will focus on the use of imaging to measure hypoxia, proliferation
and enzyme function. 
Hypoxia occurs to a variable extent in tumours and is an important determinant of
therapeutic response and survival. We have developed SR 4554 as a magnetic reso-
nance spectroscopy (MRS)-compatible probe for the measurement of hypoxia. The
design features of SR 4554 were consistent with its in vivo pharmacokinetics. Proof
that retention of SR 4554 is hypoxia-dependent was provided by its enzymology,
subcellular distribution in spheroids and tumour retention. Differential retention was
demonstrated in tumours with different radiobiological hypoxic fraction and
following modulation by carbogen and hydralazine. Based on its interesting proper-
ties, SR 4554 has been selected for clinical development and is now in Phase 1 trials. 
There is the need to develop new assays, which can be used to evaluate novel
mechanism-based cytostatic agents in patients. Towards this end, we are developing
2-[11C]thymidine and 2¢-[18F]fluorothymidine for measuring antiproliferative activity
by positron emission tomography (PET). Proof that these probes can measure the inhi-
bition of proliferation in the absence of tumour shrinkage has been provided for
trichostatin-A in HT29 tumour bearing mice. The relationship between inhibition of
proliferation and specific effects of the drug including inhibition of histone de-
acetylase and histone H4 hyperacetylation has been studied. Clinical validation of 
2-[11C]thymidine has also been performed. The retention of 2-[11C]thymidine was
shown to correlate with MIB 1 index in gastrointestinal cancers of patients. 
Dihydropyrimidine dehydrogenase (DPD) is the proximal and rate limiting
enzyme in the catabolism of 5-fluorouracil. Large variations in enzyme expression
occur and have been shown to influence the pharmacodynamics of 5-fluorouracil.
Eniluracil is a mechanism-based inactivator of DPD. Proof that eniluracil acts in a
predictable manner in patients was provided by studying the in vivo pharmacokinetics
of 5-[18F]fluorouracil (5-[18F]FU). The rapid conversion of 5-[18F]FU by normal liver
(the organ with the highest DPD activity) to [18F]fluoro-b-alanine, as well as the
hepatobiliary excretion of [18F]fluoro-b-alanine bile conjugates were inhibited by
eniluracil. In the tumours of these patients, the reduction in catabolism led to a signif-
icant increase in tumour 5-[18F]FU+anabolite levels. Knowledge obtained from these
studies has been used to assess existing and novel biomodulators of 5-fluorouracil. 
2.2
OPTIMISATION OF REDUCTASE ENZYMES FOR USE IN
HYPOXIA REGULATED GENE DIRECTED ENZYME PRODRUG
THERAPY RL Cowen1, KJ Williams1, AV Patterson2, SK Robinson1, 
F Sheppard1, BA Telfer1, L-Y Lian3, IJ Stratford1, 1School of Pharmacy,
University of Manchester, Manchester, M13 9PL, UK, 2Auckland Cancer
Society Research Centre, Faculty of Medical and Health Sciences, University
of Auckland, Private Bag 92019, New Zealand, 3Department of Biomolecular
Sciences, University of Manchester Institute of Science and Technology,
Manchester M60 IQD, UK 
Regions of low oxygen tension (hypoxia), which exist within most solid tumours, can
be exploited as a tumour specific condition leading to the development of bioreductive
drugs, which are specifically activated to become cytotoxic within hypoxic cells. Here
we present a gene therapy strategy that exploits hypoxia in tumours using it as a
tumour specific trigger to achieve overexpression of reductase enzymes. These
enzymes can donate single electrons (1e–) and can thereby activate any prodrug with
an appropriate 1e– reduction potential. This will increase the efficacy of bioreductive
agents, the activation of which will be tightly controlled by hypoxia at both a
transcriptional and metabolic level. 
When cells become hypoxic, a tissue stress response is activated to increase
expression of genes involved in energy metabolism and angiogenesis. Activation of
these hypoxically inducible genes involves cis-acting hypoxia responsive elements
(HRE). By introduction of HRE sequences within the promoter region of a therapeutic
transgene cassette it is possible to hypoxically regulate the expression of the trans-
gene. We have generated stable HT1080 human fibrosarcoma cell lines transfected
with a bicistronic cassette encoding for human cytochrome P450 reductase (P450R)
and green fluorescent protein (clone R9), or GFP reporter alone (clone GFP5), under
the transcriptional regulation of the HRE derived from the phosphoglycerate kinase 1
gene (PGK-1). When grown as tumour xenografts in nude mice, the R9 and GFP-5
cells show similar growth rates and response to radiotherapy with a single dose of 
10 Gy. Combining radiotherapy with administration of the bioreductive drug, 
RB6145 had no effect on the efficacy of 10 Gy in the GFP-5 tumours, but led to a 50%
cure rate (tumour free for 100 days following therapy) in the R9 group. 
We are now evaluating the use of recombinant adenoviral vectors to achieve the
high levels of tumour specific P450R expression that will be required in an effective
therapy. We have also identified an alternative HRE sequence from lactate dehydroge-
nase A which will provide us with increased hypoxia responsive gene expression and
most recently we are investigating ways of optimising the reductase enzyme itself by
retargeting the enzyme to a different subcellular compartment. 
2.3
INTEGRATING THE TRANSCRIPTIONAL RESPONSE TO
HYPOXIA AND IONIZING RADIATION – APPLICATIONS FOR
GENE THERAPY S Robinson, A Patterson, N Chadderton, K Williams, 
R Cowen, I Stratford, Experimental Oncology Group, School of Pharmacy
and Pharmaceutical Sciences, University of Manchester, Oxford Road,
Manchester M13 9PL, UK 
Neoplastic cells sense hypoxia and respond by altering the expression of a variety of
genes, primarily through a HIF-1 dependent trans-activation of hypoxia responsive
elements (HREs). HREs have been employed to transcriptionally target gene expres-
sion to hypoxic tumours. Rather than just optimising the hypoxia-responsiveness of
potential chimaeric promoters, we have attempted to develop dual hypoxia and X-ray
inducible promoters, such that the combination of both stimuli might provide a
greater-than-additive effect upon transcriptional output. 
A number of early response genes are induced in response to ionising irradiation
(e.g. c-fos, egr-1, UpA). This response is known to be dependent upon the presence of
serum response elements (SREs or CarGs; CC[A/T]6 GG) within the promoter
regions. A chimaeric promoter was constructed, composed of the short X-ray respon-
sive Egr-1 promoter (425 b.p.) fused to a pentamer of the Epo gene minimal HRE
(140 b.p.). The promoter was introduced into the pGL3 basic luciferase reporter
vector. A number of HRE-driven luciferase constructs were also made. Each vector
was transiently transfected into a panel of human carcinoma cell lines and their
response to either hypoxia (1% O2), X-rays (5 Gy), or both stimuli, were tested. 
In vitro the pGL3.egr-1 plasmid was responsive to 5 Gy, the pGL3.Epo.egr-1
vector was responsive to both stimuli, with the combination of hypoxia and X-rays
potentiating the expression of luciferase. A response to X-rays as well as hypoxia was
seen in the HT1080 cell line but not in the MDA468s. Further improvements to the
chimaeric promoter were explored by utilising the minimal CarG elements (juxta-
posed by the ELK-1 binding sites), preliminary results suggest that their response may
also be cell line dependent. This data demonstrates that it is possible to create a ubiq-
uitous X-ray and hypoxia responsive chimaeric promoter. 
2.4
MANIPULATION OF P450 GENE EXPRESSION IN TUMOURS; 
A NOVEL APPROACH FOR TARGETED ACTIVATION OF
BIOREDUCTIVE PRODRUGS SR McKeown, CM Hughes, G Keilty, 
HO McCarthy, M Murray, DG Hirst, T Robson, School of Biomedical
Sciences, University of Ulster, Jordanstown, N. Ireland, UK 
We are developing a gene-directed enzyme prodrug therapy (GDEPT) strategy to
enhance the metabolism of a novel bioreductive drug, AQ4N. Bioreductive drugs are
metabolically activated in the hypoxic cell environment allowing effective targeting
of hypoxic radioresistant tumour regions. We aim to achieve additional layers of
selectivity by using an X-ray inducible promoter linked to our therapeutic gene
(cytochrome P450s). This strategy would enhance metabolism of the drug only within
the radiation field. Furthermore, normal tissue would be unaffected as the bio-
reductive drug is only activated in hypoxic conditions. We have identified human
cytochrome P4501A1 (CYP1A1) to be the major prodrug activating enzyme by in
vitro drug metabolism studies of AQ4N using a range of human supersomes
(Gentest). Further to these studies, RIF1 murine tumour cells transfected with
CYP1A1 cDNA displayed greatest DNA damage and clonogenic cell kill following
treatment with AQ4N under hypoxia. We are presently testing the ability of these
transfectants to enhance anti-tumour effectiveness of AQ4N in combination with radi-
ation in vivo. In addition, we have observed a dose dependent increase of the GFP
reporter gene using the X-ray inducible WAF1 promoter. GFP was induced 1.9, 3.1
and 4.2 fold under the control of the WAF-1 promoter by doses of 2, 4 and 6 Gy 
X-rays respectively. Interestingly, this promoter was also induced by acute hypoxia
(2 h). We now aim to link this promoter to CYP1A1 for selective activation in-vivo. Oral presentations 15
2.5
HORSERADISH PEROXIDASE AND INDOLE-3-ACETIC ACID
FOR HYPOXIA- AND RADIATION-REGULATED GENE THERAPY
OF CANCER O Greco*, GM Tozer, LK Folkes, P Wardman, SD Scott, B
Marples, M Joiner, GU Dachs, Gray Laboratory CRT, Mount Vernon Hospital,
Northwood HA6 2JR, UK 
The plant enzyme horseradish peroxidase (HRP) and the non-toxic plant hormone
indole-3-acetic acid (IAA) represent a novel combination for gene-directed
enzyme/prodrug therapy of cancer (GDEPT, Greco et al, Cancer Gene Ther 7: 1414,
2000). Transfection with the HRP cDNA followed by incubation with IAA induced
selective toxicity in a panel of cell lines of human origin. Prodrug activation was fast
and efficient. Significant cytotoxicity was induced after only 2-hours’ exposure,
which was further increased after 24-h. In transient HRP-transfectants, up to 3-log cell
kill was induced at doses of IAA non-toxic to mock transfectants expressing the
marker GFP. The HRP/IAA system was similarly effective in the tumour conditions of
anoxia and in hypoxia (0.1% O2), although different mechanisms of cytotoxicity
appear to be involved. A strong bystander effect was induced, since ~70% the popula-
tion exposed to IAA in air or hypoxia could be killed when only 5% of the cells
expressed the HRP. Conditioned-medium switch experiments showed that the toxic
metabolite is a long-lived species able to cross cell membranes, and that cell contact is
not required for bystander killing. When compared to the well-established system
HSV TK/GCV, the HRP/IAA combination showed in T24 bladder carcinoma cells
increased efficacy and selectivity in vitro, both in oxic and anoxic conditions. The
interaction of HRP-mediated GDEPT with ionising radiation was evaluated. After
pre-incubation with IAA a marked increased in sensitivity to X-rays was selectively
induced in HRP-expressing T24 cells. Sensitisation enhancement ratios (SERs) of 1.8
(0.1 mM IAA) and 3.1 (0.5 mM IAA) were measured. No significant difference in the
response to radiation was observed in HRP- cells in the presence of the prodrug.
Activated IAA has previously been observed to react with DNA (Folkes et al,
Biochem Pharmacol. 57: 375, 1999) and to deplete glutathione, which could lead to
sensitisation to radiation. 
To specifically target the radio-and chemoresistant population in solid tumours, the
HRP gene was placed under the control of hypoxia and/or radiation responsive
promoters. Five copies of hypoxia responsive elements (HREs) from the PGK-1 or the
EPO gene were inserted in the basal cytomegalovirus (bCMV) promoter. After 24 h-
hypoxic incubation, the EPO and the PGK-1 HREs induced a 30–40 fold and a 5–6
fold increase in HRP expression respectively. Selective HRP production in irradiated
cells was achieved by using radiation responsive CArG elements (Marples et al, Gene
Therapy 7: 511, 2000). After 5 Gy X-irradiation, a selective 2–3-fold increase in
transgene expression was detected. 
2.6
HYPOXIA-INDUCIBLE GENE EXPRESSION IN MACROPHAGES:
ROLE OF HIFs- 1 AND -2, AND USE OF cDNA ARRAYS TO
IDENTIFY UP-REGULATED GENES B Burke, D Gill, M Wells, CE Lewis,
Tumour Targeting Group, Section of Pathology, Division of Genomic
Medicine, University of Sheffield Medical School, Sheffield S10 2RX, UK 
Hypoxia is a common feature of solid tumours. Macrophages migrate continually into
tumours from the bloodstream, and congregate in large numbers in hypoxic sites,
playing an important part in stimulating tumour angiogenesis. However, the effects of
hypoxia on gene expression have not been characterised in human macrophages. In
this study we have first determined the effect of hypoxia on the level of two related
transcription factors, hypoxia-inducible factor -1 and -2 (HIFs-1 and -2) in primary
human macrophages in vitro. We then used cDNA array hybridisation to identify
hypoxia-induced changes in the level of mRNA for 1205 different genes in
macrophages. We show that, contrary to previous reports, hypoxic human
macrophages produce abundant HIF-1 (in vitro and in various types of human
tumours), and that although they also produce HIF-2, this is less abundant than HIF-1.
We also show that exposure of primary macrophages to 0.5% oxygen increased
mRNA levels for a number of genes including matrix metalloproteinase 7 (MMP 7 or
matrilysin), vascular endothelial growth factor (VEGF), erythrocyte glucose trans-
porter 1, and EGF response factor 1 (ERF1). The promoters of a number of these
hypoxia-regulated genes contain hypoxia-responsive elements (HREs), short DNA
sequences known to bind HIFs, leading to enhanced expression of the associated
genes. As the HREs of these genes are clearly active in hypoxic macrophages, they
have the potential to be used in a novel gene therapy which would employ
macrophages to carry hypoxia-activated therapeutic genes into hypoxic tumour sites.
This approach could also have utility in the treatment of other diseases in which
macrophages accumulate in hypoxic/ischemic tissues (e.g. in joints affected by
rheumatoid arthritis). 
2.7
THYMIDINE PHOSPHORYLASE INDUCES CARCINOMA CELL
OXIDATIVE STRESS AND PROMOTES SECRETION OF
ANGIOGENIC FACTORS NS Brown1, A Jones2,3, C Fujiyama2, AL Harris2, 
R Bicknell1, 1Molecular Angiogenesis Lab, and 2Molecular Oncology Lab,
ICRF, WIMM, JR, Hospital, Oxford, UK, 3Department of Urology, Churchill
Hospital, Oxford, UK 
Introduction Thymidine phosphorylase (TP) is a potent angiogenic factor that corre-
lates with poor prognosis in a wide variety of tumours (1). TP is not secreted by the
carcinoma cell, and its angiogenic activity is known to be dependent upon the catabo-
lism of thymidine to thymine and 2-deoxy-D-ribose-1-phosphate (2dDR1P) (2). It has
remained unclear why this reaction stimulates new vessel growth. We have studied
transfected bladder carcinoma cell lines to determine the mechanism by which TP
causes angiogenesis. 
Methods RT112 cells were transfected with full-length human TP cDNA to give
the cell line RT112-TP, and were transfected with an empty vector to give the control
cell line RT112-EV. The cells were then exposed to 200 mM thymidine for 16 hours,
leading to high levels of thymidine catabolism in RT112-TP. 
Results When exposed to thymidine, the oxidative stress marker haem oxygen-
ase-1 was induced 4-fold within RT112-TP, but was not significantly induced within
RT112-EV. The increase in HO-1 was blocked by both antioxidants and by excess
thymine. Thymidine catabolism by TP therefore induces carcinoma cell oxidative
stress. In these oxidatively stressed carcinoma cells, secretion of the angiogenic factor
vascular endothelial growth factor was increased 2-fold, production of interleukin-8
went up 6-fold, and matrix metalloproteinase-1 levels were elevated 1.5-fold (3). 
Conclusions It appears that TP promotes angiogenesis by inducing carcinoma cell
oxidative stress. When TP overexpressing carcinoma cells experience oxidative stress
they increase their production of the secreted angiogenic factors VEGF and IL-8.
These will act directly upon endothelial cells to cause vascularisation of the tumour. 
1. N.S Brown & R. Bicknell, (1998) Biochem J 334: 1–8 (review) 
2. A. Moghaddam. et al (1995) Proc Natl Acad Sci USA 92: 998 
3. N.S. Brown et al(2000) Cancer Res 60: 6298–6302 
3.1
PHASE III TRIAL OF DOSE ESCALATION USING CONFORMAL
RADIOTHERAPY IN PROSTATE CANCER: SIDE EFFECTS AND
PSA CONTROL D Dearnaley1, E Hall1, C Jackson1, D Lawrence1, 
R Huddart1, R Eeles1, J Gadd2, A Warrington2, M Bidmead2, A Horwich1
1Institute of Cancer Research/2Royal Marsden NHS Trust, Sutton & London 
Background This prospective randomised phase III single centre trial was designed
to evaluate the side effects and efficacy of dose escalation using CFRT and in a 2´2
factorial design to study the appropriate radiotherapy planning ‘safety margin’. 
Patients and Methods 126 men with localised prostate cancer were treated with
initial (3–6 months) androgen suppression and then randomised between (1) standard
dose (SD) CFRT treatment (64 Gy) or standard treatment with high dose (HD) boost
(74 Gy) and (2) Phase I margin of 1.0 cm (M1.0) or 1.5 cm (M1.5). The boost (10Gy)
was delivered to the prostate only with no margin. Patients were stratified according to
risk of seminal vesicle involvement (SV+) and treatment volumes defined appropri-
ately. Patient and tumour characteristics were evenly balanced between the groups
with median age of 67 years, presenting PSA of 15 ng/ml and low/moderate risk of
SV + of 29%/71%. Study endpoints included acute toxicity (RTOG), late side effects
(RTOG/LENT-SOM), biochemical (PSA) control, 2 year post-treatment biopsies,
clinical disease control and overall survival. 
Results Median follow-up after CFRT was 3.5 years (range 0.6–5.2 years). Acute
side-effects: There was no observed difference in bowel side effects between
randomised groups, but bladder side effects were more common both during and after
treatment in M1.5 compared with M1.0 group (P = 0.002), and after treatment in the HD
compared with SD group (P= 0.006). Late side-effects: For all patients bowel or bladder
RTOG ³ 3 toxicity was uncommon (bowel 2%, bladder 5%). Bowel side-effects (RTOG
³ 2) were seen in 23%/11% of HD/SD groups respectively (P = 0.06) and 21%/13% of
the M1.5/M1.0 groups respectively (P = 0.2), but all three men with grade ³3 side
effects were in the HD M1.5 group. Bladder side-effects (RTOG³2) were recorded in
18%/13% of HD/SD groups (P = 0.3) and 21%/10% of the M1.5/M1.0 groups (P =.07)
respectively. A similar rate of impotence (59%) was seen in all groups. 
Biochemical control PSA levels were consistently ≤2ng/ml in 82% and 69% of
HD and SD group after completion of treatment (P = 0.06). Control rates were 75%
and 76% for M1.0 and M1.5 groups. 
Comment These results suggest dose escalated CFRT can be given with an accept-
able level of acute/late toxicity, but volume and dose effects are detectable for bladder
and bowel side effects. Early follow-up data suggests a possible improvement in
biochemical control with increased dose, but there was no evidence to suggest any
advantage for the larger radiotherapy margin. The results have been used to inform the
MRC Trial RT01 Data Monitoring Committee and will be combined in meta-analysis
with the national trial.16 Oral presentations
3.2
PROSTATE BRACHYTHERAPY; A PROSPECTIVE ANALYSIS OF
UROLOGICAL SYMPTOMS. Declan Cahill. Stephen Langley,
Abdul Ismail, Robert Laing. St. Lukes Cancer Centre, Royal Surrey Hospital,
Guildford GU2 5XX 
Prostate brachytherapy is becoming an accepted treatment for organ confined prostate
cancer, and 12-year PSA free survival rates are equivalent to those achieved with
surgery. However, increased urinary symptoms occur in a significant proportion in the
first year. Data on urinary symptoms have been collected prospectively on the 71
patients treated with permanent iodine implants These data include formal uro-
dynamic measurements (UDS) pre-treatment in a sub-group. 
1) Do baseline assessments or dosimetry predict symptom score after treatment? 
2) Can pre-treatment uro-dynamics determine who will go into retention? 
Methods A descriptive cohort analysis. Baseline assessments collected were: 
1) IPSS (prostate international symptom score) graded mild 1–7: moderate 8–19:
severe 20–35 
2) prostate volume according to ultrasound 
3) urodynamics categorised as stable or unstable: obstructed or non-obstructed or
equivocal 
Dosimetry was expressed as D90 (the dose delivered to 90% of the prostate). V100
(volume of prostate receiving 100% of the prescribed dose) and V150 (150%). 
Outcome measures were IPPS at 6, 12, 24, 39 weeks, and the need for intermittent
self-catheterisation (ISC) 
Results Of the 71, 12 were excluded from the analysis, as baseline data were
incomplete at this time. 
Mean IPSS (95% Confidence interval) by weeks since treatment 
0 6 12 26 39 
Cohort 7.7 20.8 15.8  15.5  12.1   
(6.3–91) (17.7–23.7) (13.2–18.5) (12.6–18.7) (7.9–16.3)
Mild 3.3 18.2 13 12.6  7.3   
(2.4–4.1) (14.0–22.4) (9.9–16.1) (7.1–18.2) (2.8–11.8)
Mod/sev 11.9 23.5  18.5  17.1 15.9   
(10.4–13.5) (19.4–27.7) (14.5–22.1) (14.1–1.25) (9.8–8.22)
P* <0.001 0.032 0.015 0.052 0.012 
N 59 35 31 28 16 
*Two-sample t test with equal variances 
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Those patients with mod/severe IPPS pre-treatment had significantly worse
symptoms on follow up. 
There were no differences in IPSS in those receiving external beam as well as
brachytherapy compared to brachytherapy alone.
Urodynamic data have been collected on 33 individuals of whom 19 were
obstructed. 8 equivocal and 6 unobstructed. To ease symptoms 14/71 required ISC for
a short time of whom none were in the unobstructed group. 1 patient, who was in the
obstructed group, required TURP. 
Neither post implant dosimetry or prostate volume significantly predicted
outcome. 
Conclusion In this pilot study we have shown that patients’ symptoms increase
following brachytherapy and the degree of symptoms are related to the initial
symptom score and obstruction on UDS. However at 39 weeks, the symptom scores
are returning to baseline. The addition of external beam RT, prostate volume, V150
were not predictive of symptom score. Prostate brachytherapy remains a well-
tolerated effective treatment for appropriately selected patients. 
3.3
A PHASE II STUDY OF SYNCHRONOUS CHEMO-
RADIOTHERAPY FOR LOCALLY ADVANCED BLADDER
CANCER. SA Hussain1,2, DD Moffitt1, JG Glaholm2, D Peake2, DMA
Wallace2, ND James1,2 1CRC Institute for Cancer Studies, University Hospital
Birmingham. 2Queen Elizabeth Hospital, Edgbaston, Birmingham, UK
Purpose We have previously reported results of a phase I/II study of synchronous
chemo radiotherapy with 5-fluorouracil (5-FU) and Mitomycin-C (MMC) in patients
with muscle invasive bladder cancer. We now report updated results from our ongoing
phase II trial with the optimised regimen. 
Method Patients with T2-T4 N0/Nx M0 muscle invasive bladder cancer were
entered into this single centre study. Patients received 55 Gy/20 fractions/4 weeks of
radiotherapy. Concurrent chemotherapy was given with MMC 12 mg/m2 day 1 and 5-
FU 500 mg/m2/24 hours for 5 days during weeks one and four of radiotherapy. The
primary end point for the study was pathological response rate at 3 months; secondary
endpoints were toxicity, disease-free and overall survival and bladder preservation
rates. 
Results A total of 35 patients have entered the trial from March 1998 to January
2001 and are available for toxicity assessment at the censor date of 10th February
2001. Median age was 68 (range 38–79) years, 27 males and 8 females; 3 patients
were node positive; T2 9 (25%), T3a 5 (14%), T3b 11 (32%), T4 10 (29%), TCC
grade 2, 8 (23%) and grade 3 27 (77%); 16/35 patients had hydronephrosis. Toxicity
was mild to moderate (NCI-CTG grade 3: thrombocytopenia 4/35; diarrhoea 4/35). 26
patients underwent local response assessment, 5 patients were not evaluated due to
early metastatic spread though their were no clinical suggestion of bladder failure, 1
patient died from probably unrelated cardiac cause, 3 patients are not yet due cysto-
scopic assessment. Pathological complete response was seen in 19/26 (73%) patients
at 3 months. Estimated 12-month survival was 63%. Two patients have required
salvage cystectomy and, of patients still alive, 18/20 retain a functioning bladder at
median follow up of 14 months. 
Conclusion Chemoradiotherapy with the 5-day schedule is feasible in the manage-
ment of elderly patients. The regimen has encouraging activity with acceptable toxi-
city in relatively poor prognosis patients. A randomised trial using the 5-day schedule
compared to radical radiotherapy alone with standard versus reduced volume radio-
therapy has the MREC approval and is due for national launch in July 2001. 
3.4
AN EVALUATION OF HUMAN SKIN EPIDERMAL CELLS FOR
HYPER-RADIOSENSITIVITY N Shah, MC Joiner, MI Saunders,
Marie Curie Research Wing and Gray Laboratory Cancer Research Trust,
Mount Vernon Hospital, Northwood, Middlesex, UK 
Introduction The laboratory phenomenon of hyper-radiosensitivity (HRS) describes
an excess of cell kill at doses below 1 Gy relative to that predicted by the linear
quadratic model. Mathematical modelling for malignant glioma suggests a doubling
or more in the therapeutic index if radiation doses are given at 0.5 Gy per fraction
three times a day to a total dose of 73.5 Gy. The epidermal basal cell layer of human
skin, chosen as a model of normal tissue, is studied to verify the clinical existence of
HRS. 
Methods Epidermal basal cell density (BCD) was assessed by manual counting
after H&E fixation of skin samples obtained by punch biopsy. The BCD of unirradi-
ated normal human skin from 3 volunteers was studied to assess baseline variability.
Twenty four patients receiving radical radiotherapy to the pelvis had the skin dose
over the lateral radiation portals modified to compare doses of 0.5 Gy vs 1.0 Gy or
more. Radiotherapy doses at the epidermal basal cell level were verified using ther-
moluminescent dosimeters (TLD). Skin biopsies, from both sides, were obtained until
completion of radiotherapy. The changes in BCD were compared using non linear
regression analysis. 
Results Normal unirradiated skin BCD demonstrates significant intrapatient and
interpatient variation (P < 0.0001). Analysis of 24 patients demonstrate a 2.03 (95%
CI 1.80–2.28) fold statistically significant reduction in BCD, termed the Enhancement
Ratio (ER), in favour of the lower skin dose (0.48 Gy vs 1.22 Gy). For individual
patients, a statistically significant BCD reduction in favour of the low dose side was
demonstrated in 14 (58%) patients (ER range 1.60–7.07). A non significant ER was
demonstrated in 10 (42%) patients. 
Conclusion In spite of baseline BCD variability, these results suggest HRS at the
epidermal basal cell layer of skin. Individual patient analyses suggest that this may not
be a universal phenomenon but this is subject to statistical uncertainty. The assess-
ment of other cell kinetic parameters will help determine the true magnitude of HRS
in human skin. Oral presentations 17
3.5
TARGETED RADIOIMMUNOTHERAPY – NOVEL DELIVERY OF
CORONARY ARTERY RADIATION EC Sims1, MEB Powell2, 
MT Rothman1,3, TD Warner1, 1Dept. of Cardiac, Vascular & Inflammation
Research, William Harvey Research Institute, 2Dept. of Clinical Oncology &
3Dept. of Cardiology, Bart’s & The London, Queen Mary’s School of Medicine
& Dentistry, London, UK 
Introduction Coronary artery brachytherapy is the most exciting breakthrough in
cardiology of the last decade. Currently used techniques necessitate irradiation imme-
diately post angioplasty, which leaves little scope to investigate key radiobiological
issues. These include defining the optimal dose and fractionation schedule, timing of
radiation delivery and radioprotection. 
By inserting an antigen-coated stent at the time of angioplasty, we have developed
a new technique enabling targeted radiotherapy to be delivered after angioplasty using
radiolabelled antibody. This innovation allows the important issues of dose scheduling
to be evaluated and minimizes radiation exposure to the medical team. 
Method 15 mm metal stents were incubated in biotin-BSA (expt. 1), digoxin-BSA
(expt. 2) or PBS as control to adsorb antigen. Commercially available anti biotin anti-
body and anti digoxin Fab fragments were labelled with 125I in an iodination suite
(24–32 kBq/mg). Antigen-coated stents were placed individually in the aortae of
heparinised Wistar rats using an angioplasty balloon and the aortae were repaired.
Return and maintenance of blood flow was confirmed by Doppler ultrasound of the
iliac vessels. Radiolabelled antibody was then injected intravenously and the animals
were sacrificed after 2 hours. The stents were carefully dissected out and captured
radioactivity was recorded in a gamma counter. Organ samples were counted simulta-
neously to assess potential toxicity of the treatment allowing antibody distribution and
clearance to be estimated. 
Results Groups quoted as mean +/– standard error. Uptake of radioantibody by
antigen-coated stents was significantly greater than control with minimal uptake by
uncoated stents. Clearance of radioantibody was related to molecular weight being
quicker with smaller Fab fragments. 
Expt. Antigen N = Counts/ kBq Antibody P value 
minute bound (ng/stent)
1 biotin 3 27271 0.46 14.1 +/– 1.8 0.002 
PBS 3 1071 0.02 0.6 +/– 0.2 0.002 
2 digoxin 4 42108 0.70 29 +/– 1 <10–4
PBS 4 1752 0.03 1.2 +/– 0.4  <10–4 
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Conclusion This is the first study to demonstrate successful delivery of radiation
to stents after the angioplasty procedure. Future aims are to maximize antigen loading
on stents and to develop an antibody–antigen pair with optimised pharmacokinetics.
This exciting technique promises immense therapeutic benefit in humans. 
3.6
A NATIONAL ONLINE AUDIT OF RADIOTHERAPY IN HEAD AND
NECK CANCER ND James1, G Robertson2, H Forbes3, K Jones3, 
B Cottier3, 1CRC Institute for Cancer Studies, Birmingham, 2Beatson
Oncology Centre, Glasgow, 3National Cancer Services Analysis Team,
Clatterbridge Centre for Oncology, Wirral
Introduction Radiotherapy practice in head and neck cancer was identified as a
target for a national audit as there are published data on the effects of delays in treat-
ment and gaps in therapy on survival and published guidelines on their management.
We utilised a novel online (www.canceruk.net/natcansat/audit.htm) audit tool to
rapidly collect data (summarised in an accompanying abstract). 
Method An electronic form in 2 parts was distributed to 56 eligible radiotherapy
centres. The first part examined the centre’s policies for managing gaps in therapy, the
second collected data on 50 consecutive patients treated in that centre. Data entry was
facilitated and standardised by the use of ‘drop-down’ lists. Patient data were
collected on: primary site; stage; date of decision to treat; date of start and end of
radiotherapy; prescribed dose and fractionation, steps taken to ensure timely comple-
tion of radiotherapy. 
Results 55 centres returned data on a total of 2620 patients (2.9:1 male:female),
mean age 62.8, interquartile range 54–72 years. Average delay to starting RT was 40
days with only 6 centres having an average wait of < 28 days. Commonest fractiona-
tion schedules were 54–55 Gy/20 fractions, 60–66 Gy/30–33 fractions, and
50 Gy/15–16 fractions. An analysis of fractionation by primary site, stage and centre
is underway. Treatment was completed within 2 days of target in 78% of cases; an
analysis of treatment prolongation by primary site, stage, fractionation and centre will
be presented. Seven centres had no policy for dealing with treatment interruptions.
Overall, 1467 (55%) patients had 1 or more treatment interruptions (service days
47%; machine breakdown 14%; staff shortages 2%, toxicity 12%; compliance 7%;
patient died on treatment 3%; public holiday 67%). Of patients whose treatment was
interrupted, 56% still completed on time due to compensatory steps: other machine
37%; treat twice 17%; biological compensation 18%; weekend or public holiday 5%;
no attempted compensation 32%. 
Conclusions This dataset gives a unique snapshot of radiotherapy practice in the
UK for head and neck cancer for 1999–2000. It also sheds light on significant varia-
tions in the quality of care and shows a widespread failure to meet national targets (for
waiting times) or guidelines (for compensation for gaps), which has serious implica-
tions both for patient outcomes and for implementation of the National Cancer Plan. 
3.7
CLINICAL OUTCOME OF A RANDOMISED TRIAL OF CT
SIMULATION VERSUS CONVENTIONAL SIMULATION FOR
PALLIATIVE TREATMENT OF ADVANCED LUNG CANCER M McJury2, 
S Pledge3, P Fisher3, G Brown1, C Anthony1, M Hatton3, J Conway2, 
MH Robinson1, 1YCR Department of Clinical Oncology, 2Department of
Radiotherapy Physics, 3Department of Radiation Oncology – all at Weston
Park Hospital, Sheffield S10 2SJ
Introduction 113 patients were entered into a randomised trial comparing the use of
CT simulation and conventional simulation in the palliative treatment of advanced
lung cancer. The use of CT simulation was associated with markedly reduced treat-
ment volumes compared to conventional simulation. This is the final report of the
study detailing the clinical outcomes. 
Patients and methods Complete patient data was available for 78 patients.
Clinical assessment of the symptomatology was made pre-treatment and one month
after treatment. Patient diary cards were completed for one month post-treatment. 
Results 50% of patients in each arm received 17 Gy in 2 fractions and the other
50% 36 Gy in 12 daily fractions. The WHO score and general condition improved in
43% of those treated using conventional simulation compared to 30% and 20%
respectively, of those using CT simulation. The figures for cough were 36.7% vs
38.9%; sputum production 40% vs 35.7%; haemoptosis 91.7% vs 100%; shortness of
breath 59.4% vs 44.8%. 
Table % Patients with symptomatic improvement 
Conventional Simulator (CS)/Virtual Simulator (VS) 
Cough  Sputum Shortness of breath 
CS VS CS VS CS VS 
17 28.6 42.1 33.3 43.7 50 44.4 
36 33.3 35.3 30 21.4 62.5 41.7 
The patients in the CT simulator arm tended to have a slightly worse WHO score at
outset. 
Conclusion There were differences in clinical outcome between the arm of the
trial which will be discussed. 18 Oral presentations
3.8 
IMPROVED SYMPTOM RELIEF WITH FRACTIONATED
PALLIATIVE RADIOTHERAPY IN PATIENTS WITH LUNG
CANCER MN Gaze, CG Kelly, GR Kerr, A Cull, RH MacDougall, GCW
Howard, VJ Cowie, A Price, A Gregor, Department of Oncology, Western
General Hospital, Edinburgh
Background Individual randomised trials have not previously suggested a benefit in
survival or symptom relief from fractionated regimes of palliative thoracic radio-
therapy (TRT) in patients with lung cancer. 
Aims To determine whether fractionated TRT offers better symptom relief, quality
of life or survival than single fraction TRT. 
Methods Randomised controlled trial of 30 Gy in 10 daily fractions (F) vs 10 Gy
single fraction (S) TRT. The principal endpoint was physician-assessed symptom
score for cough, chest pain, dyspnoea, haemoptysis and dysphagia. Subsidiary
endpoints were survival and quality of life. Symptom scores were compared using the
Wilcoxon signed rank test. 
Results 148 patients were randomised into groups matched for age, gender,
histology, performance status and initial total symptom score (TSS). Patients
randomised to F had lower TSS at 1st review (P = 0.014) and when the best TSS at
either 1st or 2nd review (1 and 3 months) were compared (P = 0.001). This group also
had better scores at either review for dyspnoea (P = 0.010), chest pain (P = 0.014) and
cough (P = 0.029). Overall, TSS improved following TRT in 28/60 assessable patients
with S and 40/57 with F (c2 = 6.64, df = 1, P = 0.01). Median survival was 23
weeks with S and 28 weeks with F (P = 0.197). Patients with S were also more
anxious than patients with F (1st review P = 0.01, either review P = 0.003). 
Conclusions Fractionated TRT offered better symptom relief and reduced anxiety
compared to single fraction palliation, but did not increase survival. 
4.1
DNA METHYLATION IN OVARIAN CANCER G Strathdee, 
K Appleton, J Plumb, R Brown, CRC Department of Medical
Oncology, Beatson Laboratories, Glasgow University, Glasgow G61 1BD, UK 
DNA methylation within the promoter regions of genes has been shown to be associ-
ated with transcriptional silencing. In recent years a growing list of genes have been
found to be aberrantly methylated in tumours, including many genes known to be
important in tumour development. We have previously shown that cisplatin resistant
derivatives of the ovarian carcinoma cell line A2780 have lost MLH1 expression due
to promoter methylation. Furthermore inhibition of DNA methylation results in a
reduction in promoter methylation, re-expression of MLH1 and sensitisation to
cisplatin and other chemotherapeutic drugs both in vitro1 and in vivo in mouse
xenografts2. Based on these studies, a clinical trial of the combination of carboplatin
and decitabine (2¢ deoxy-5-azactyidine, a DNA methyltransferase inhibitor) is sched-
uled to begin in early 2001. 
To further define the role of aberrant methylation in ovarian cancer, we have
assessed the methylation status of ten loci in a panel of 93 ovarian tumours using
methylation specific PCR. Seven of the ten loci (BRCA1, HIC1, hTR, MINT25,
MINT31,  MLH1,  p73) studied showed significant levels of methylation ranging
between 10 and 54% of the tumours and the majority of the tumour (71%) exhibited
methylation of at least one loci. Grossly normal tissue, taken from adjacent to 18 of
the tumours, showed little or no evidence of methylation at the ten loci investigated.
Immunohistochemical analysis of one of the genes investigated, MLH1, determined
that methylation was associated with reduced expression in the tumours, however,
immunohistochemical analysis of BRCA1 found no apparent loss of expression in
tumours exhibiting methylation of this gene. Similar to reports in colon and gastric
cancer, the ovarian tumours show evidence of a CpG island methylator phenotype
(CIMP) in which multiple genes are concurrently methylated in a single tumour.
However, unlike colon and gastric cancer, the results suggest the presence of at least
two groups of CIMP+ tumours, each susceptible to methylation of a different group of
genes. 
1. Strathdee G, MacKean M, Illand M, Brown R (1999) Oncogene 18: 2335 
2. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R (2000) Cancer Research
60: 6039 
3. Strathdee G, Appleton K, Illand M, Millan DWM, Sargent J, Paul J, Brown R,
American Journal of Pathology, in press
4.2
NOVEL PROTEIN INTERACTIONS OF MISMATCH REPAIR
PROTEINS hMLH1 AND hMSH2 M MacPartlin1, E. G. Homer1, 
H Robinson1, D Gillespie2, R Brown1, 1CRC Department of Medical Oncology
and 2CRC Beatson Institute, CRC Beatson Laboratories, Garscube Estate,
Switchback Road, Bearsden, Glasgow, G61 1BD, UK 
Mismatch repair proteins have a central role in correcting mismatches in DNA occur-
ring during DNA replication and have been implicated in engagement of apoptosis
and cell cycle arrest induced by a number of important anticancer drugs. The MutS
homologue, MSH2, is involved in recognising mismatches and DNA damage. The
function of the MutL homologue MLH1 remains obscure, although clearly is required
for mismatch repair and signalling apoptosis from DNA damage induced by agents
such as cisplatin. 
We have screened a yeast-two-hybrid cDNA library, from normal human breast,
for proteins interacting with the MMR protein hMLH1. Amongst the interacting
proteins identified was the proto-oncogene c-MYC. The c-MYC proto-oncogene and
its heterodimeric partner MAX have been implicated in apoptosis, cell cycle arrest
and genetic instability, although are proposed to mainly function by influencing gene
transcription. The interaction between MLH1 and c-MYC is further supported by
pull-down experiments using GST-hMLH1 fusion proteins and co-immunoprecipita-
tion from human and avian cell extracts. The carboxy terminus of human and avian 
c-MYC, which contains the MAX binding basic region/ helix-loop-helix/“leucine
zipper” (b/HLH/LZ) domain, can interact with MLH1 and a C-terminus (amino acids
515–756) fragment of MLH1. MYC mutants with C-terminal truncations of the
Leucine Zipper motif of 10 and 27 amino acids, which have previously been shown to
abolish MYC transforming activity and MAX binding, fail to bind MLH1. 
Using a GST-Max fusion protein in pull-down experiments we have also shown
that MAX is capable of interaction with the MMR protein hMSH2. The MAX:MSH2
interaction is also observed by co- immunoprecipitation of human cell extracts. Thus,
it appears that c-MYC is capable of interacting with the MutL homologue MLH1,
while its heterodimeric partner MAX can bind to the MutS homologue MSH2. 
4.3
LOSS OF MGMT AND HMLH1 EXPRESSION IN SPORADIC
COLORECTAL CANCER A Jubb1, SM Bell1, S Gray1, L Harkins1, 
J Stahlschmidt1, P Quirke1, 1Academic Unit of Pathology, Algernon Firth
Building, University of Leeds, Leeds, West Yorkshire, LS2 9JT, UK 
Genetic instability is at a premium during tumorigenesis, to further tumour evolution.
Epigenetic inactivation of either O6-methyguanine-DNA methyltransferase (MGMT)
or the human MutL homologue (hMLH1) may result in such a mutator phenotype.
MGMT is principally involved in the repair of alkylating lesions, which might other-
wise give rise to guanine to adenine mutations, for instance in the Ki-Ras oncogene.
hMLH1 is involved in mis-match repair defects that are responsible for instability of
homopolymeric runs on replication. 
We have assessed the expression of MGMT and hMLH1 at the protein level in 284
Dukes’ stage B colorectal tumours. In the analysis, we employed an automated
immunohistochemistry protocol, a relatively simple technique that is applicable to
large sample numbers. Total loss of MGMT staining was observed in 22% of cases. In
a further 28%, positive staining in less than 50% of the tumour was recorded as
‘partial loss’. Interestingly, MGMT expression was 30% lower in tumours from
female cases, as compared to male cases. This is indicative of sex-specific aetiologies
and molecular profiles. MGMT acts through a suicidal mechanism and, accordingly,
this semi-quantitative analysis is a direct reflection on the cell’s capacity for repairing
alkylated DNA-adducts. hMLH1 was absent in 16% of tumours, 50% of which were
negative for MGMT, suggesting these two events occur independently. Loss of
hMLH1 expression was not associated with gender. 
We are currently undertaking further work to determine COX-2 expression in the
same series. Recent publications suggest that loss of expression from these three gene
promoters may define a methylator phenotype with distinct clinico-pathological char-
acteristics. This profile may identify patients who are less susceptible to conventional
chemotherapy with 5-fluorouracil or to treatment with non-steroidal anti-inflamma-
tory drugs. However, tumours that are negative for MGMT may be susceptible to
chemotherapy with alkylating agents. Oral presentations 19
4.4
SUPPRESSION OF VITAMIN D SIGNALLING IN PROSTATE
CANCER BY A MECHANISM INVOLVING HISTONE
DEACETYLATION KL Smith, LP O’Neill, BM Turner, MJ Campbell, Divisions
of Medical Sciences, and Immunity & Infection, University of Birmingham,
B15 2TH, UK 
Various data support a role for 1a, 25, Dihydroxyvitamin D3 (1a, 25(OH)2D3) in regu-
lating the growth of the normal prostate gland yet prostate cancer cells appear signifi-
cantly less sensitive to this action. The mechanism for this is unclear as vitamin D3
receptor (VDR) content, mutational status or transcriptional activity do not correlate
directly with sensitivity to 1a, 25(OH)2D3. Previously we demonstrated that inhibitors
of histone deacetylation (sodium butyrate (NaB) and trichostatin A (TSA)) synergised
with 1a, 25(OH)2D3 to induce apoptosis in LNCaP, PC-3 and DU-145 prostate cancer
cells [1]. We hypothesized that transcriptional silencing of a subset of antiproliferative
genes, by a process involving histone deactylation, altered the sensitivity to 1a,
25(OH)2D3. To elucidate further the mechanism we have treated PC-3 cells with
1a, 25(OH)2D3 (100 nM) alone or in combination with TSA (15 nM) and undertaken
cDNA microarray analysis to identify changes in critical target genes and examined
the acetylation of histones. 
The cDNA microarray analysis revealed treatment with 1a,25(OH)2D3 alone actu-
ally upregulated many genes associated with cell cycle progression and mitosis for
example, Cyclin D1 (2.4 fold), CDK4 (2.9 fold), the mitosis protein EB-1 (3.8 fold),
the DNA replication factor MCMS (6.3 fold) and PCNA (4.4 fold) and the anti-
apoptosis bcl-x (2.5 fold). Co-treatment with TSA down-regulated many of these
events but additively or synergistically upregulated a number of growth inhibitory
genes such as p21(waf1/cip1) (3.5 fold), the putative tumour suppressor ZO-1 (2.5 fold),
and the scaffold protein zyxin (2.2 fold). Cumulatively the gene changes were consis-
tent with the observed growth inhibition and induction of apoptosis. Furthermore, we
have analysed the acetylation status of histone H4 following individual or co-treat-
ment of agents for 2 hr. We found that 1a,25(OH)2D3 alone had no effect on the basal
level of acetylation, whereas TSA showed a slight increase in the higher isoforms of
acetylated H4. However, the co-treatment resulted in a dramatic and rapid increase in
the levels of acetylated H4. 
These data support a model whereby TSA synergises with 1a,25(OH)2D3 by
hyperacetylation of histones thereby altering the transcriptional profile and restoring
the normal antiproliferative signalling. 
Rashid SF et al (2001). Oncogene (In press). 
4.5
THE ROLE OF DAMAGE SENSING/PROCESSING GENES IN
THE RADIATION RESPONSE OF HAEMOPOIETIC COLONY-
FORMING CELLS KP Hoyes, SA Roberts, JH Hendry, Paterson Institute for
Cancer Research, Christie Hospital, Manchester M20 4BX, UK 
Purpose Recovery of bone marrow from cytotoxic injury is mediated by the survival
characteristics of its progenitor cells. The progenitor cell response is coordinated by a
variety of genes in particular those involved in the regulation of DNA repair, cell
cycle progression and apoptosis. We have assessed the role of a variety of relevant
genes in the survival of haemopoietic progenitors after high dose-rate irradiation by
comparing responses in mutant/null and wild type mice. 
Methods Femoral bone marrow was isolated from nod/scid mice or animals null
for bcl-2, bax, atm, p21 or p53 and their wild type counterparts. Marrow suspensions
were irradiated in vitro with Cs-137 gamma-rays then assayed for in vitro CFC by
culture in semisolid medium containing IL-3. Granulocyte/macrophage colonies were
counted after 7 days growth. 
Results CFC isolated from bcl-2 deficient mice were slightly more radiosensitive
than in wild-type animals at doses to 2 Gy but not at higher doses. In contrast, CFC
from bax-/-animals were more resistant than in wild-types at doses to 2 Gy but not at
higher doses. CFC from nod/scid and atm-/- mice were markedly more radiosensitive,
with increasing survival differentials at higher doses, whilst CFC from p53-/- animals
were more radioresistant. The response of CFC from p21-/- mice was only slightly
more sensitive than in wild-type animals. The results also indicate that the genetic
background of the host mouse plays little role in these CFC responses, at least
regarding the influence of p53 in CFC radioresponse. 
Conclusions These data provide quantitation and comparison of the influence of
these mutant and null genes, in particular those encoding (components of) the impor-
tant damage- sensing gene products atm and DNA-PK, in the radiation response of
haemopoietic progenitor cells. The survival-related genes bcl- 2 and bax play a role in
CFC responses, which diminishes at higher doses. In contrast, the influence of atm
and DNA-PK increases with increasing dose, so that these dominate the response
compared to bcl-2 and bax, as well as compared to p53 and p21. The data contribute
to knowledge of the molecular control of radiation response of this one normal cell
type. Other cell types are also being studied. 
4.6
INHIBITION OF MONOCYTE AND MACROPHAGE CHEMOTAXIS
BY HYPOXIA AND INFLAMMATION – A POTENTIAL
MECHANISM MJ Grimsha, FR Balkwill, ICRF Translational Oncology
Laboratory, St. Bartholomew’s and The Royal London School of Medicine
and Dentistry, Charterhouse Square, London, UK 
Tumor-associated macrophages accumulate in areas of necrosis that are likely to be
hypoxic. This may be because chemotaxis of monocytes and macrophages towards
several chemokines is rapidly (within 60–90 min) inhibited by hypoxia. Exposure to
the inflammatory cytokine TNF-a, which is also found in the tumor microenviron-
ment, has a similar effect on macrophage migration. We report here that neither
changes in mitochondrial respiration nor intracellular pH are involved in hypoxic
macrophage migration arrest. However, hypoxic inhibition of migration was
mimicked using chemical activators of hypoxia-inducible factor-1 and reversed by
transcriptional inhibition. We used RAP-PCR, a differential display technique, to
investigate which genes were upregulated within 90 minutes exposure to hypoxia. Of
several thousand mRNAs screened, only one was consistently upregulated by hypoxia
and this was identified as MAPK phosphatase 1 (MKP-1), which modulates MAPK
activity. Levels of MKP-1 mRNA and protein were rapidly elevated in monocytic
cells and primary macrophages after hypoxia or TNF-a treatment. The functional
significance of MKP-1 was illustrated by hypoxia-induced decreases in phosphoryl-
ated MAPK in these cells and arrest of chemotaxis by MAPK inhibitors. 
One of the important events in an ‘emergency stop’ response that leads to accumu-
lation of macrophages in areas of tumor hypoxia may be inhibition of the chemo-
attractant signalling cascade. 
4.7
CYTOCHROME P450 CYP1B1: A NOVEL MECHANISM OF
DRUG RESISTANCE, Morag CE McFadyen1, William T Melvin2,
Graeme I Murray1, 1Department of Pathology, 2Department of Molecular and
Cellular Biology, University of Aberdeen, Aberdeen, AB25 2ZD, UK 
CYP1B1 is a member of the xenobiotic metabolising cytochrome P450 enzymes. This
superfamily of constitutive and inducible haemoproteins are central to the oxidative
metabolism of wide range of substrates including endogenous compounds involved in
cell signaling, environmental carcinogens and anti-cancer drugs. Our previous studies
have shown CYP1B1 protein to be to be expressed at significant levels only in tumour
tissue being specifically localised to the tumour cells1. Our current studies are investi-
gating CYP1B1 activity in a number of human tumours and its role in the metabolism
of anti-cancer drugs in these tumours. 
CYP1B1 activity can be measured by ethoxyresorufin-o-deethylase activity using
the EROD assay. Our initial findings investigating ethoxyresorufin-o-deethylase
activity indicate that CYP1B1 is active in a number of human tumours (100–800
fmol/min/mg of protein). Moreover, this activity can be inhibited by co-incubation
with the CYP1B1 inhibitor alpha-naphthoflavone. The over-expression of active
CYP1B1 in human tumours is important possibly as a mechanism of drug resistance.
Several cytochrome P450 enzymes are capable of the bio-transformation of a number
of anti-cancer drugs. We have recently shown several of these drugs to be substrates
for CYP1B1, and our in vitro studies are now providing evidence for a functional role
for CYP1B1 in drug resistance. 
Using the MTT assay the cytotoxic profile of CYP1B1 with a number of anti-
cancer drugs is currently being evaluated with a Chinese hamster ovary cell line
known to express active CYP1B1 and a parental non-expressing CYP1B1 cell line.
Our results show that on exposure to docetaxel a significant (P = 0.03) increase in
resistance to the cytotoxic effects of docetaxel was observed between the parental cell
line (IC50 = 22 nM) and the cell line expressing CYP1B1 (IC50 = 100 nM). In addition,
co-incubation with alpha-naphthoflavone, reversed the resistance to docetaxel in the
CYP1B1 expressing cells. The resistance to the cytotoxic effects of docetaxel in those
tumours expressing CYP1B1 may have important clinical implications. It is also
likely that the over-expression of active CYP1B1 is a general mechanism of drug
resistance. Moreover, the ability to overcome this drug resistance with the appropriate
CYP1B1 inhibitors could be developed clinically. 
1. Murray GI, Melvin WT, Greenlee WF, Burke MD. 2001 Annu Rev Pharmacol
Toxicol 41 (in press). 20 Oral presentations
4.8
TUMOUR PHYSIOLOGY AS AN IMPORTANT AND NEGLECTED
CAUSE OF DRUG RESISTANCE IF Tannock, Princess Margaret
Hospital and University of Toronto, Toronto ON M5G 2M9, Canada 
Clinical drug resistance of solid tumours may be caused by cellular mechanisms (e.g.
P-glycoprotein, Pgp); by mechanisms that depend on the microenvironment, espe-
cially the requirement for drugs to penetrate tumour tissue to reach all of the target
cells; and on repopulation of tumour cells between courses of chemotherapy. 
We have grown tumour cells on collagen-coated porous teflon membranes to form
multicellular layers (MCL) up to 200 mm thick. MCL share features of solid tumours
including rare tight junctions and an extracellular matrix. We have studied the time-
dependent penetration through MCL of several anticancer drugs used commonly 
for the treatment of solid tumours: cisplatin, doxorubicin, 5FU, gemcitabine,
methotrexate, mitoxantrone, paclitaxel and vinblastine. Penetration of all drugs is
slow compared with that through the teflon membrane alone and is particularly poor
for the weak bases doxorubicin and mitoxantrone (< 10% penetration compared to the
teflon membrane alone at 6 hours). Factors that limit net uptake of drug into cells
(including expression of Pgp) increase drug penetration through tissue, while reversal
of Pgp decreases tissue penetration of its substrates. The tissue penetration of doxo-
rubicin and mitoxantrone may be improved substantially by agents that inhibit the
sequestration of these drugs in acidic endosomes of cells. 
Repopulation of surviving tumour cells between successive treatments is a process
known to influence outcome of radiotherapy and is likely to be even more important
in the longer intervals between cycles of chemotherapy. It might be inhibited selec-
tively by biological agents such as inhibitors of growth factor receptors that are
expressed on tumour cells. 
The literature on drug resistance is dominated by studies of molecular mecha-
nisms. While important, other causes of effective drug resistance such as limited
tissue penetration by drugs and repopulation of tumour cells between cycles of
chemotherapy may be (a) equally important and (b) susceptible to modification to
improve therapeutic index. 
Supported by grants from the Canadian Institute of Health Research and the
National Cancer Institute of Canada. 
5.1
THE WNT-APC-b CATENIN PATHWAY IN PHYLLODES TUMOURS 
EJ Sawyer1,2,3, AM Hanby2, C Gillett2, A Rowan1, R Poulsom4, 
P Ellis3, IPM Tomlinson1, 1Molecular and Population Genetics Lab &
4Histopathology Unit, ICRF, 44 Lincoln’s Inn Fields, London WC2A 3PX,
2Hedley Atkins/ICRF Breast Pathology Laboratory, 3Guys, Kings, 
St Thomas1 Cancer Centre, Guy’s Hospital, London SE1 9RT, UK 
Phyllodes tumours are uncommon fibroepithelial mammary lesions which may show
a spectrum of behaviour from benign through to sarcomatous transformation. In a
previous study of phyllodes tumours we have shown that both the stroma and epithe-
lium contain distinct molecular changes suggesting that both are part of the neoplastic
process. In view of this finding we decided to study stromal-epithelial interactions in
these tumours by examining the Wnt-APC-b catenin pathway. 
b catenin and cyclin D1 immunohistochemistry was performed on 119 tumours.
72% of tumours had nuclear b catenin staining in the stroma and in 57% this was
moderate or strong. In 17 cases (14%) this nuclear staining was more prominent in the
stromal cells adjacent to the epithelium. Of the 8 malignant tumours in the series, 7
showed no or weak nuclear staining and this relationship was statistically significant
(P < 0.025). 19% of the phyllodes tumours showed moderate or strong cyclin D1
staining and this correlated with nuclear stromal b catenin staining (P = 0.05). 
46 of the tumours were analysed for b catenin mutations using SSCP and
sequencing. No b catenin mutations were found in any of the tumours. Loss of
heterozygosity (LOH) of the microsatellite marker, D5S346, was used to infer APC
mutation. Only one phyllodes tumour showed LOH at D5S346 and this tumour had
moderate nuclear b catenin staining. 
Wnt 5a expression was detected using in situ hybridisation. Thirteen cases were
chosen to reflect the different b catenin staining patterns (10 benign, 3 malignant). 
All tumours showing strong nuclear b catenin staining expressed epithelial Wnt 5a 
(P < 0.0015) and in the 2 cases with the subepithelial distribution of b catenin staining
there were also subepithelial clusters of Wnt 5a expression. 
This study shows that abnormal nuclear b catenin accumulation is common in the
stroma of benign phyllodes tumours and that one of the down stream targets of this is
cyclin D1. Significantly in malignant tumours this abnormal b catenin expression is
lost. The correlation of strong b catenin staining and Wnt 5a overexpression together
with the similar subepithelial distributions suggests that epithelial Wnt 5a signalling
drives proliferation of the stroma in benign phyllodes tumours and that proliferation
becomes Wnt independent in malignant tumours. 
5.2
ADRIAMYCIN/CMF (A/CMF) FOR HIGH RISK BREAST CANCER 
IN THE UK IS AS GOOD AS (CALGB9344) AC/TAXOL)-ANGLO-
CELTIC COOPERATIVE ONCOLOGY GROUP (ACCOG) RCF Leonard10, 
E Toy1, T Evans2, J Levay3, I Kennedy4, R Grieve5, T Perren6, A Jones7, 
J Mansi8, J Crown9, G McIntyre10, A Anderson10, S Povey10 and D Cameron10,
Edinburgh10, Cardiff1, Glasgow2, Ipswich3, Hamilton NZ4, Coventry5, Leeds6,
London7,8, Dublin9
The Milan A/CMF 12 cycle regimen remains the most effective adjuvant treatment
policy with published long-term disease-free and overall survival data for multiple
node-positive breast cancer. It was adopted by ACCOG as the standard arm of its first
high dose trial in high risk disease (ACCOG1). The data from this completed trial are
not yet mature but the regimen has been used in many of our centres as a standard
protocol for high risk disease outside the trial. From 6 UK Irish and New Zealand
centres, 328 patients with stage 2 disease received 9–12 courses of A/CMF combined
in 287 cases with adjuvant radiotherapy, routinely between courses 5 and 6. Median
dose delivered was 100% of planned but in 40 patients there were 1–10 weeks aggre-
gate dose delays and in 171 patients, dose reductions. Main toxicities were alopecia
(which typically recovered during CMF phase) and grade 3 or 4 neutropenia which in
19 patients caused sepsis. There were no treatment-induced deaths. 
This was a particularly poor risk population; only 2 were node–ve, 16 were 1–3
node+ve; 178 4–9 node+ve and 150 10+ node+ve. 95 were ER–ve and 15 of these and
all ER +ve had tamoxifen for 5 years on completion of chemotherapy. 
At a median follow-up of 2.8 years, there have been 19 local relapses, 87 distant
relapse and one patient with both. Relapse free and overall survival are shown with
the CALGB 9344 data shown for comparison.
Regimen Node number 2 YR DFS 2 YR OS 
AC/TAX 4–9 85% 94% 
A/CMF 4–9 85% 93% 
AC/TAX 10+ 69% 85% 
A/CMF 10+ 75% 90% 
This audit is further evidence of the efficacy, tolerability and safety of a regimen
that should be a gold standard against which any complex and expensive regimen
requires to be tested; for example the recently launched ‘TACT’ trial. 
5.3
ADJUVANT TAXANES FOR EARLY BREAST CANCER – CLINICAL 
UNCERTAINTY EXISTS P Barrett-Lee2, J Bliss1, P Ellis3, E Hall1, 
L Johnson1, D Lawrence1, 1CTSU, Section of Epidemiology, Institute of
Cancer Research, Sutton, 2Velindre Hospital, Cardiff, 3Guy’s, King’s & 
St Thomas’s Hospital, London, on behalf of the TACT Trial Management Group†
The Taxotere as Adjuvant Chemotherapy (TACT) Trial tests whether there is an
increase in 5-year disease-free and overall survival of early breast cancer patients
randomised to receive 4 cycles of sequential docetaxel (Taxotere) following 4 cycles
of FEC, compared with UK anthracycline-based chemotherapy of similar duration. In
November 2000, a questionnaire circulated to 205 potential TACT Trial participants
based at 94 UK centres aimed to a) confirm that target recruitment is achievable, 
b) ascertain whether a choice of control arm (8 ´ FEC or E-CMF) is necessary, and 
c) establish the level of clinical uncertainty about the use of adjuvant taxanes for
different patient groups. 
Target recruitment 132 replies from clinicians at 86 centres were received (114
within 2 weeks). The combined anticipated annual accrual was 2431. Even if this level
were halved, target recruitment (3340 over 3 years) is achievable. 
Choice of control arm 83 (62%) clinicians preferred FEC as the control arm and
49 (38%) E-CMF. This translates to 1436 and 995 patients per year respectively. 
Of 123 respondents who indicated whether the withdrawal of their chosen control
arm would affect their recruitment, 60 (49%) of respondents (contributing 1269 (54%)
patients) suggested that it would; 63 (51%) of respondents (contributing 1095 (46%)
patients) suggested it would not. Withdrawal of the FEC control arm would result in
the loss of up to 767 (33%) potential patients. Withdrawal of the E-CMF control arm
would result in the loss of up to 540 (23%) potential patients. 
Level of clinical uncertainty for taxane usage Uncertainty was greatest in the
<50 age group, and for node +ve patients aged 50–70. For patients aged <50, ER –ve,
with 1–3 nodes +ve, 88% of respondents expressed clinical uncertainty. Only 1% of
respondents expressed clinical uncertainty for patients aged >70, ER +ve, and 
node –ve. 
Conclusions Recruitment into the TACT Trial should meet or exceed target.
Clinical opinion is divided over the choice of control arm, however more respondents
opted for 8 ´ FEC than E-CMF. Clinical uncertainty about the use of adjuvant taxanes
is widespread and varies greatly according to patient characteristics. 
†D Bloomfield, L Branston, M Brunt, D Cameron, D Dodwell, H Earl, L Foster, 
A Harnett, J Hearn, P Hopwood, J Houghton, S Houston, A Jones, S Johnston 
T Perren, C Poole, I Smith, M Stead, C Twelves, M Verrill, J Yarnold Oral presentations 21
5.4
CAPECITABINE NAMED PATIENT PROGRAM FOR PATIENTS 
WITH ADVANCED BREAST CANCER: THE UK EXPERIENCE 
RCF Leonard, A Anderson1, R Salazar, C Twelves2, A Hutcheon, D Bissett3,
T Bates4, A Chaturvedi5, S Chan, J Carmichael6, on behalf of the UK
Capecitabine Audit Group, 1Edinburgh, 2Glasgow, 3Aberdeen, 4Oxford, 5Hull,
6Nottingham, UK 
102 patients with advanced breast cancer received capecitabine in a UK open access
programme and have been analysed for response and toxicity. Median age was 53.2
(range 30–95). Patients had received between 0–4 prior chemotherapy regimens for
advanced disease. 58% of patients had visceral disease and median number of sites of
disease was 1. 60.8% had previously received anthracyclines, 25.5% taxoids and 6.9%
infusional 5-FU. A median of 5 cycles were given. 
Dose reductions occurred in 32.4% of patients (10.2% of cycles). The mean dose
intensity was 95%. There were 3 complete responders, 17 partial responders, and the
total objective response rate was 19%. Stable disease was achieved in 46% and
progression was seen in 30%. Toxicity is tabulated. 
Event Grade 1 (%) Grade 2 (%) Grade 3 (%) Grade 4 (%) 
Neutropenia 2.0 1.0 2.0 1.0 
Thrombocytopenia 3.9 2.0 1.0 0.0 
Mucositis 1.0 2.9 2.0 0.0 
Fatigue 12.7 3.9 2.9 1.0 
PPE 15.7 11.8 7.8 0.0 
Diarrhea 21.6 5.9 4.9 2.0 
Nausea 23.5 5.9 1.0 0.0 
Vomiting 11.8 2.9 2.0 0.0 
We conclude that capecitabine was well tolerated and active in extensively
pretreated patients with advanced breast cancer. Toxicity was manageable at the
recommended dose of 1250 mg/m2 b.i.d. for 14 days q21 days. 
5.5
INFUSIONAL 5-FLUOROURACIL AND VINORELBINE FOR 
METASTATIC BREAST CANCER – A NEW REGIMEN WITH HIGH
ACTIVITY, N Stuart1, M McIllmurray2, SO’Reilly3, C Price4, S Johnston5, 
J Joffe6, F Neave7, T Perren8, T Crosby9, 1Ysbyty Gwynedd Bangor,
2Lancaster Royal Infirmary, 3Clatterbridge Centre for Oncology, 4Bristol
Centre for Oncology, 5Royal Marsden Hospital, 6Huddersfield Royal Infirmary,
7North Middlesex Hospital, 8St James’ Hospital, Leeds, 9Velindre Hospital,
Cardiff, UK 
An increasing number of drugs are available for the treatment of metastatic breast
cancer (MBC) but the optimum regimen is not defined. There remains a need for regi-
mens that are active and well tolerated particularly after anthracyclines (A) or taxanes.
Vinorelbine (VRB) has shown high single agent activity and low toxicity. 5-fluoro-
uracil (5FU) given by continuous infusion (CI) has shown activity in heavily pre-
treated MBC, and has a different toxicity profile to VRB. Sixty-four patients (pts)
with MBC have been enrolled in a phase II study of VRB 30 mg/m2 day 1 and 8 each
21 days and 5FU 200 mg/m2/day given by CI. Data is available on the first 31 pts. All
pts had received prior treatment with A (27) or mitoxantrone (4), 4 as adjuvant
therapy with relapse within 12 months and 27 for metastatic disease. 10 pts had 2 or
more prior regimens. All pts had measurable disease, ECOG PS ≤ 2, and normal liver
and renal function. Median age was 51 (27–78). Achieved overall dose intensity was
VRB 15 mg/m2/week (75%), 5-FU 157 mg/m2/day (78%) with delay and dose reduc-
tion largely due to neutropenia. 11 episodes of neutropenic sepsis occurred but no
treatment related deaths. 10 patients suffered significant problems from their sub-
clavian lines (thrombosis 3, displacement 3, pneumothorax 1, infection 1, other 2) and
5 had to stop treatment because of this. Incidence of other toxicity was generally low.
Grade 1–2 and 3–4 toxicity occurred with the following incidence. Neutropenia 19%,
65%, thrombocytopenia 29%, 0%; anaemia 94%, 0%, nausea and vomiting 23%, 7%;
mucositis 23%, 4%; constipation 19%, 4%; peripheral neuropathy 17%, 3%; diar-
rhoea 14%, 4%; hand foot syndrome 7%, 5%. Tumour response occurred in 17 (54%)
of patients. Median duration of response in responding pts was 18 weeks. VRB + 5FU
by CI is active and generally well tolerated in MBC after treatment with anthracy-
clines. Neutropenia is the main toxicity. Future studies will explore the role of oral
vinorelbine and the oral 5FU analogues with the aim of developing an active, well
tolerated and convenient oral regimen for MBC. 
5.6
IMPACT OF YOUNG AGE ON LOCAL RECURRENCE AFTER 
BREAST CONSERVING THERAPY IH Kunkler1, W Jack1, G Kerr1,
U Chetty2, M Dixon2, T Anderson2, A Rodger3, RCF Leonard1, APM Forrest2,
1Dept of Clinical Oncology, 2Edinburgh Breast Unit, Western General
Hospital, Edinburgh, 3Monash University, Victoria, Australia 
Background There is increasing evidence that young age may be an independent risk
for local recurrence (LR) after breast conserving surgery (BCS) and postoperative
breast irradiation (RT). 
Aim A retrospective audit of BCS + RT was undertaken to assess the impact of
prognostic factors including age on the risk of LR. 
Methods Between 1981–1993, 929 patients with T1-2, NO-1, MO breast cancer
were treated at the Western General Hospital by BCS and RT. 729 [79.2%] were carci-
nomas of no special type, 45 [6.9%] lobular and 58 [6.3%] tubular. Mean tumour size
was 23.7 mm (range 3–50 mm). Median age was 53 years. Minimum follow up was 6
years, apart from 2 patients lost to follow up at 3 years. Re-excision of the margins
was carried out in 118 patients. Axillary surgery was either by a level 3 clearance (166
[18%]) or a 4-node lower axillary node sample (721 [78.3%]) followed by axillary RT
in N+ [28%]. Standard radiotherapy was 45 Gy in 20 fractions over 4 weeks with a
boost (864) by electrons (595 [60.9%]) or iridium implant (252 [29.2%]). Axillary RT
was given to 472 patients. 609 [66%] were treated with adjuvant tamoxifen and 79
[8.6%] with CMF. Local failure was defined as relapse in the breast. Distant failure
included patients with concurrent local relapse. 
Results A local relapse occurred in 82 patients, distant relapse in 178 patients and
regional relapse in 78 patients. The 5 year actuarial breast relapse rate was 4.8% at 5
years, 10.1% at 10 years and 14.6% at 15 years. The 5 year local relapse by age cohort
is shown in the Table. 
Table: Breast relapse rate by age cohort 
<30 years 30–39 40 –49  50–59  60–69  70+  
years years years years years
33.3% 14% 5.7% 2.6% 1.8% 12.2% 
Conclusion Breast relapse rates in women under the age of 40 were particularly
high, even with attention to obtaining clear margins. These higher rates may reflect in
part undetected multifocality in the radiodense breast in younger women. The higher
risks of breast relapse in young women should be explained to patients in whom breast
conserving therapy is being considered. 
5.7
USING HISTOPATHOLOGIC DATA TO IMPROVE THE
DETECTION RATE OF GERMLINE BRCA1 MUTATIONS G
Mitchell1,2, D Easton3, R Pears4, J Harroway5, RA Eeles1,2, 1Institute of
Cancer Research, Surrey, UK, 2Royal Marsden NHS Trust, London, UK,
3CRC Strangeways Research Laboratories, Cambridge UK, 4St George’s
Hospital, London UK, 5Christchurch Hospital, Christchurch, New Zealand 
Aim To improve the selection of families for diagnostic genetic testing for germline
mutations in the BRCA1 gene by using pathologic data from breast cancer
histopathology reports to enrich risk estimates based on pedigree data. 
Introduction Most UK cancer genetics clinics offer BRCA 1/2 mutation testing to
families with ³ 4 cases of young onset breast and/or ovarian cancer (a priori probability
> 60% using Claus risk estimates) to ensure a cost-effective mutation detection rate. A
family has to be of sufficient size to fulfil these stringent criteria, potentially excluding
an important number of families with mutations. Incorporating pathologic features of
breast cancer may help to improve prediction of mutation status as pathologic differ-
ences have been detected between sporadic and BRCA1-associated breast cancers. 
Methods 226 individuals undertaking a diagnostic test for germline BRCA1 muta-
tions between June 1991 and March 1999 at the Royal Marsden, St George’s and Guy’s
Hospitals, and for whom histopathology records could be identified, were studied. 
Results 20 germline BRCA 1 mutations were detected. Mutation carriers were of
significantly higher tumour grade than non-carriers. Vascular invasion, histological
phenotype and DCIS were not predictive of mutation status. Table 1 summarizes the
distribution of BRCA 1 mutations using Claus risk estimates, presence of ovarian
cancer and pathologic grade. 30% of mutation carriers were ‘low risk’ but all had
grade 3 tumours. Combining tumour grade with family history discriminated well
between 132 lower risk families, potentially excluding 34% of them (‘low risk’,
pathological grades 1&2) from genetic testing. 
Conclusions The addition of pathological grade helps identify families with BRCA
1 mutations which do not fulfil UK pedigree criteria for mutation testing with poten-
tial personal benefit to these families and cost benefit to the NHS 
Table 1
No. patients No. of patients  
BRCA 1 mut+ BRCA1 mut– 
(% of all  (% of all 
BRCA1 non-BRCA1 
carriers) patients)
Claus risk >90% ovarian cancer+ 5 (25) 12 (6) 
Claus risk >90% ovarian cancer- 5 (25) 49 (24) 
Claus risk <90% ovarian cancer+ 4 (20) 19 (9) 
Claus risk <90% ovarian cancer- 6 (30) 126 (61) 
Tumour: grade 1 0 (0) 10 (5) 
grade 2 0 (0) 33 (16) 
grade 3 6 (30) 59 (29) 
Unknown grade 0 (0) 10 (5) 22 Oral presentations
6.1
THE TERMINAL 11A.A. CYTOPLASMIC TAIL OF THE b6 
INTEGRIN SUBUNIT IS ESSENTIAL FOR THE PROMOTION OF
avb6-DEPENDENT INVASION MR Morgan*, GJ Thomas1, PM Speight1, 
IR Hart, JF Marshall, Richard Dimbleby Department of Cancer
Research/ICRF Lab, St. Thomas’ Hospital, London, Eastman Dental
Institute, University of London, UK 
The integrin avb6 is expressed de novo on keratinocytes in both squamous cell carci-
noma (SCC) and wound healing, which are both entities involving invasive behaviour.
Previously we have shown that upregulation of avb6, the fibronectin/tenascin
receptor, promotes a more malignant phenotype in SCC cells involving increased
invasive and migratory capabilities. 
The b6 subunit has an unique C-terminal 11 amino acid sequence which may be
responsible, through intracellular signalling, for these altered functional effects in
SCC cell lines expressing high levels of avb6. 
To investigate this possibility we have created a panel of SCC cell lines, using
retroviral transfer of appropriate cDNAs, which express either the wild-type b6 or a
mutant b6 lacking just the terminal 11 a.a. tail. VB6 and V3b6∆ 11 aa cell lines were
generated which express similar levels of avb6; a cell surface level approximately 10
times as that expressed by the null transfectant cell line, C1. 
Haptotactic migration assays, toward fibronectin, showed similar levels of migra-
tion (11.53% + 11.78%) by both the VB6 and the V3b6∆ 11aa cell lines. The migration
of V3b6∆ 11aa was reduced to C1 levels by the avb6 blocking antibody, 10D5,
demonstrating that the truncated b6 subunit in the V3b6∆ 11aa cell line still functions
as a fibronectin receptor. 
In marked contrast, however, in transwell invasion assays VB6 cells invaded
through Matrigel to a significantly greater extent (100%) than the C1 null transfectant
cell line (33.9%) and the V3b6∆ 11aa line (36.2%). This invasive behaviour was avb6
and MMP-9 dependent and suggests that the unique 11 a.a. extension of b6 is essential
for this more aggressive phenotype. Densitometric analysis of zymography results
showed that C1 and V3b6∆ 11aa cells exhibited reduced levels (46.4% + 49.4% reduc-
tions) of secreted MMP-9 activity when compared with VB6 cells. Thus, the terminal
11 a.a. sequence of b6 integrin promotes invasion, at least in part, by increasing the
expression of activated MMP-9. 
6.2
ASSOCIATION OF SCAR WITH THE SRC TYROSINE KINASE: 
CONSEQUENCES FOR SCAR REGULATION VG Brunton1, 
P Timpson1, NO Carragher1, L Machesky2 and MC Frame1, 1Beatson Institute
for Cancer Research, Switchback Road, Glasgow, G61 1BD, 2School of
Biosciences, University of Birmingham, Birmingham, B15 2TT, UK 
The Arp2/3 complex regulates the assembly of new actin filament networks at the
leading edge of cells where it is located in a variety of cell types. Proteins of the
WASP family and related protein group the Scars, bind directly to the Arp2/3 complex
and stimulate its ability to promote the nucleation of new actin filaments in response
to Cdc42 and Rac activation. These proteins are thought to act as intermediates
between growth factor receptors, via adaptor molecules such as Nck and Grb2, and the
actin cytoskeleton, however their regulation within the cell is not fully understood.
The non-receptor tyrosine kinase Src phosphorylates and associates with a number of
proteins involved in the regulation of the actin cytoskeleton and the aim of this study
was to establish whether Src regulates the activity of Scar1. Using a GFP-tagged Src
we have shown that the localisation of Src within the cell is under the control of the
Rho GTPases: Src localises to focal adhesions in a Rho-dependent manner and subse-
quent activation of Rac or Cdc42 results in its localisation to lamellipodia or filopodia
respectively. Using immunofluorescence we have also demonstrated that Scar co-
localises with Src at focal adhesions, lamellipodia and filopodia. Scar associates with
Src in immune complexes, which is mediated via the SH3 domain of Src. The associ-
ation of Scar with Src results in the phosphorylation of Scar and we are currently
assessing whether this alters the ability of Scar to associate with the Arp2/3 complex.
We have also found that Scar is cleaved by calpain, a protease found in focal adhe-
sions, whose activity is regulated by Src (Carragher et al, J. Biol. Chem. 276:
4270–4275, 2001). This represents another mechanism whereby Scar activity may be
regulated within the cell. 
6.3
EXPRESSION OF MAP KINASE KINASE-5 (MEK5) IN HUMAN 
PROSTATE CANCER BL Jenkins, PB Mehta, CN Robson, DE Neal,
HY Leung, Department of Surgical and Reproductive Sciences, Medical
School, University of Newcastle-Upon-Tyne, NE2 4HH 
MAP kinase kinase-5 (MEK5) is a protein kinase upstream of the MAP kinases. It has
a pivotal role in cell signalling1. MEK5 specifically phosphorylates ERK5 which acti-
vates the MEF2 transcription factors. A consequence of this is increased transcription
of c-jun and cellular proliferation2,3. Previous work by our group has demonstrated the
loss of a DNA fragment in the highly metastatic cell line LNCap-LN3 when compared
to the parental cells. The fragment showed 100% homology to the 3’untranslated
region of mek5. Immunostaining for MEK5 has been performed on a range of resected
prostate cancer samples to further delineate its function. 
Materials and Methods Western blotting was performed on lysates of the above
cell lines to identify MEK5 protein expression. The filter was probed with three anti-
MEK5 antibodies to select the most efficacious one. 128 resected human prostate
cancer specimens and 10 benign hypertrophy specimens were then immunostained.
The intensity of staining was graded with two independent observers as
negative/weak or moderate/strong and the results compared with Gleason grade,
presence of metastases and survival. 
Results The BPH specimens all stained very negative/weak for MEK5. Of the
cancer specimens with Gleason grade of 4–7, 10 specimens (29.4%) stained nega-
tive/weak and 24 (70.6%) moderate/strong. In the Gleason grade 8–10 group,
14 (14.9%) stained negative/weak and 80 (85.1%) moderate/strong. Fishers exact test
revealed that this staining was significantly different (P = 0.05). A Kaplain-Meier
Survival plot revealed that higher MEK5 staining was associated with lower survival
than the group with less MEK5 staining, though not significantly different (P =
0.625). Higher MEK5 staining intensity was seen in patients with metastases
compared to those without (P = 0.03). Survival of patients with metastases was signif-
icantly less than those without (P < 0.0001). A survival plot with the two Gleason
grade groups, Gleason 2–7 and 8–10 and revealed survival was significantly different
(P = 0.008). 
Discussion MEK5 acts within a very specific cell signalling protein kinase
cascade. The loss of the mek5 fragment in the LNCaP-LN3 line may suggest a role for
this gene in metastasis. MEK5 protein expression is low in BPH, and up-regulated in
prostate cancers. Intense staining is seen in specimens with high Gleason grades and
in patients with metastases. High MEK5 expression is associated with poor survival. 
1. Zhou G, Bao ZQ, Dixon JE J Biol Chem 270(21): 12665 
2. Kato Y, Kravchenko VV, Tapping RI et al. EMBO J., 16(23): 7054 
3. Katto Y, Tapping RI, Huang S et al. Nature 395(6703): 713 
6.4
FGF-2 MEDIATES SURVIVAL OF SMALL CELL LUNG CANCER 
CELLS (SCLC) THROUGH A MEK-DEPENDENT PATHWAY:
CORRELATION WITH THE TRANSLATIONAL REGULATION OF BCL-2
FAMILY MEMBERS OE Pardo1, G Salerno1, S Raguz2, MJ Seckl1, 1Cancer
Cell Biology Unit, 2MRC Lab., Hammersmith Hospital, London W12 0NN, UK 
The role of basic fibroblast growth factor (FGF-2) has not previously been investi-
gated in the biology of small cell lung cancer (SCLC), a disease with a 5-year survival
< 5%. Here we show that FGF-2 protects SCLC cells from drug-induced cell death.
Etoposide [0.1 mM], one of the main drugs used in SCLC treatment, induced apop-
tosis in H510 SCLC cells as demonstrated by annexin V staining, cytochrome 
c release, caspase-3 activation and PARP cleavage. Addition of FGF-2 [0.1 ng/ml], 4h
prior to etoposide, inhibited the appearance of these markers and rescued the cells
from apoptosis. As FGF-2-induced the activation of both the p42/44MAPK and the
p70S6K, we tested whether these signalling pathways could be involved in preventing
etoposide-induced apoptosis. Inhibition of the p42/44MAPK, using a MEK inhibitor
(PD098059) abolished the prosurvival properties of FGF-2. However, inhibition of
p70S6K or the PI3K/PKB pathway, with rapamycin or Ly294002 respectively, did not
block FGF-2 induced survival. Time course experiments revealed that a minimum of
3h incubation with FGF-2, prior to etoposide treatment, was needed to rescue cells
from apoptosis. This did not correlate with the transient activation of p42/44MAPK
(peak at 5 min and back to control levels by 10 min) suggesting that induction of new
protein synthesis was required. This was confirmed by the observation that cyclohex-
imide, a protein synthesis inhibitor, abolished the prosurvival effect of FGF-2. We
further demonstrate that the anti-apoptotic proteins Bcl-2 and Bcl-XL was neither due
to protein stabilisation (as assessed by pulse chase) nor to an increase in mRNA
synthesis (as assessed by real time quantitative PCR), suggesting that FGF-2 regulates
the levels of these proteins at the translational level. This was further confirmed by the
lack of effect of actinomycin D on upregulation of these proteins. In addition to its
effect on the anti-apoptotic members of the Bcl-2 family, FGF-2 was able to inhibit
the induction of the proapoptotic member, Bad, by etoposide. Thus, FGF-2 appears to
act on both sides of the survival/death balance, tilting it towards cell survival. These
data suggest that FGF-2 could be involved in SCLC cell resistance to chemotherapy
and inhibition of FGF-2 signalling may provide new ways of sensitising cells to 
treatment. Oral presentations 23
6.5
CHRONIC HYPOXIA RESULTS IN DOWNREGULATION OF 
PRO-APOPTOTIC PROTEINS OF THE BCL-2 FAMILY IN A PANEL
OF HUMAN COLON CARCINOMA CELLS J Erler1, K Williams2, I Stratford2,
C Dive1, 1CRC Molecular Pharmacology Group, School of Biological
Sciences, 2Experimental Oncology Group, School of Pharmacy and
Pharmaceutical Sciences, University of Manchester, Oxford Road,
Manchester M13 9PL, UK 
Hypoxic tumours are more likely to have a poor prognosis due to resistance to radio-
and chemotherapy. These hypoxic tumours are also associated with a higher degree of
malignancy and increased ability to metastasise. Cancer cells sense hypoxia and
respond by altering the expression of a variety of genes, primarily through a HIF-1
dependent trans-activation of hypoxia responsive elements (HREs). Some of these
hypoxia-regulated genes are important for tumour growth and include VEGF, glucose
transporters, glycolytic enzymes and enzymes important in maintaining cellular pH
homeostasis. There is overwhelming evidence to show that HIF-1 deficiency
adversely effects tumour growth (e.g. Maxwell et al (1997) PNAS, 94: 8104–8109).
Since tumour growth is a balance between tumour cell proliferation and cell loss (cell
death), we have sought to define the contribution of hypoxia/HIF-1 dependent
processes that are important in apoptosis. It is known that the Bcl-2 family of proteins
play a central role in regulating the threshold for drug-induced apoptosis. We therefore
examined whether chronic hypoxia would modulate the expression level of Bcl-2
homologs in a panel of colon carcinoma cell lines (HCT116, SW480 and HT29).
These cell lines each generated elevated levels of VEGF protein under hypoxic condi-
tions and these preliminary observations would suggest the colon lines are HIF-1
proficient. Moreover, levels of five of the pro-apoptotic family proteins Bid (full
length and truncated), Bad, Bax, Bak and Nip3 were decreased in all three cell lines
exposed to hypoxia for 16 h albeit to different extents. No effect on the expression of
the anti-apoptotic proteins Bcl-2 and Bcl-xL was detected. The level of expression of
these pro-apoptotic genes in tumours in vivo is currently being assessed together with
their spacial location in relation to expression of intrinsic markers for hypoxia such as
GLUT-I and CA IX. 
6.6
FACTORS REGULATING THE PHOSPHORYLATION OF PROTEIN 
KINASE B/AKT IN HUMAN PROSTATIC CELL LINES R Michael
Sharrard, Norman J Maitland, YCR Cancer Research Unit, Department of
Biology, University of York, York YO10 5YW, UK 
Protein Kinase B (PKB), also known as Akt, is a key enzyme regulating cell survival,
motility, and gene transcription. Its downstream effectors include the apoptotic regu-
lator protein BAD, the Forkhead transcriptional regulators, GSK-3, and caspase 9.
PKB/Akt is itself regulated by phosphorylation at serine 473 and threonine 308; the
phosphorylation of these residues may be regulated by separate pathways and may
have differential effects on pathways downstream of the enzyme. PKB/Akt phos-
phorylation is influenced by soluble growth factors and by integrin-based cell-
substrate adhesion via signalling pathways involving ras, integrin-linked kinase
(ILK), and phosphatidylinositol 3-kinase (PI3K) and its product PIP3. PTEN tumour-
suppressor protein, which dephosphorylates PIP3 as well as specific protein targets,
may exert many of its effects through regulation of PKB/Akt. 
We studied the effects of integrin-based cell-substrate adhesion and serum-derived
growth factors on the phosphorylation status of PKB/Akt in cell lines derived from
human non-tumour prostate epithelium (PNT2, PNT1a), from a well-differentiated
prostate tumour (P4E6), and from prostate tumour metastases (LNCaP, PC3).
Phosphorylation of PKB/Akt was assayed by Western blotting and probing with anti-
bodies specific to the ser473-and thr308-phosphorylated protein forms. In the non-
tumour cells, maintenance of ser473 phosphorylation was dependent upon both
adhesion to a solid substrate and the presence of serum, while the tumour cells showed
only small decreases in ser473 phosphorylation in response to prevention of adhesion
or serum deprivation. In contrast, both advanced tumour cell lines were extremely
sensitive to the PI3K inhibitor LY294002 (ser473 phosphorylation reduced by 94% in
LNCaP and by 86% in PC3), while PNT2, PNT1a and P4E6 cells were markedly less
sensitive. Phosphorylation of thr308 was almost undetectable in PKB/Akt from all the
cell lines except LNCaP, in which thr308 phosphorylation showed the same pattern of
susceptibility as ser473. 
These results suggest that the regulation of PKB/Akt in normal prostatic epithelial
cells is effected through a convergence of signalling pathways from adhesion proteins
and receptors for soluble growth factors. PKB/Akt regulation in tumour cells is rela-
tively independent of these extracellular signals. The sensitivity of LNCaP and PC3
cells to the PI3K inhibitor suggests a mechanism in which PI3K activation has
become uncoupled from cell surface receptor signalling and is the predominant factor
in maintaining PKB/Akt phosphorylation. These studies suggest that drugs which
inhibit PI3K and its products may be selectively therapeutic in treatment of advanced
prostate cancer. 
6.7
MOLECULAR ANALYSIS OF BAG-1 FUNCTION IN HUMAN 
BREAST CANCER CELLS PA Townsend, R Cutress, M Brimmell
and G Packham, CRC Wessex Medical Oncology Unit, Cancer Sciences
Division, School of Medicine, University of Southampton, Southampton SO16
6YD, UK 
BAG-1 is a multifunctional protein, which associates with a variety of cellular targets
including steroid hormone receptors, BCL-2, RAF-1 kinase, the hepatocyte growth
factor receptor, the proteasome and 70 kDa heat shock proteins, HSC70 and HSP70.
BAG-1 promotes cell survival, proliferation and metastasis, alters responses to steroid
hormones and modulates the chaperone function of HSC/HSP70. BAG-1 exists as
three distinct isoforms, BAG-1/S, BAG-1/M and BAG-1/L, which originate from a
single mRNA by alternate translation initiation and are differentially localised in cells.
Our immunohistochemical analyses have demonstrated that BAG-1 is overexpressed
in the majority of invasive breast carcinomas. Nuclear, but not cytoplasmic expression
of BAG-1 is significantly inversely correlated with tumour grade and tends to asso-
ciate with improved overall survival. We have generated expression constructs that
selectively encode individual BAG-1 isoforms and in long-term clonogenic assays,
overexpression of each of the BAG-1 isoforms protects MCF7 cells from the growth
inhibitory effects of heat shock (HS). BAG-1S also protects against growth inhibition
by some but not all chemotherapeutic drugs in long term assays. To address the mole-
cular basis for this activity we analysed its interaction with putative binding partners
in breast cancer cells and demonstrated relatively strong interactions with 70 kDa heat
shock proteins, HSC70 and HSP70, modest interaction with the estrogen receptor, but
not to BCL-2. We have created deletion and point mutations and have shown that
interaction with HSC/HSP70 is mediated by the C-terminus of BAG-1. We are
currently testing these mutations in our biological assays. BAG-1, HSC70 and HSP70
all relocalise from the cytoplasm to the nucleus within 4 hours after heat shock.
Although the interaction between HSC/HSP70 and BAG-1 and the relocalisation of
HSC/HSP70 to the nucleus are not effected by detergents, BAG-1 can be extracted
from the nuclei of heat shocked cells using mild detergents. These results suggest that
the relocalisation of BAG-1 is not dependent on binding to HSC70/HSP70, and that
the association between BAG-1 and HSC/HSP70 may be disrupted by heat shock. We
are currently analysing in detail the subcellular localisation and binding interactions
of BAG-1 after heat shock, and the effect of BAG-1 overexpression on this sequestra-
tion mechanism. 
6.8
PROLIFERATION SIGNALS IN BLADDER CARCINOMA CELLS: A 
NEW APPROACH HH Seifert, S Swiatkowski, C Steinhoff, 
WA Schulz, Dept of Urology, Heinrich-Heine-University, Düsseldorf, Germany 
To investigate which intracellular signal transduction pathway might be responsible
for the increased proliferation of bladder carcinoma cells, we have chosen a new
approach by comparing the activity of target promoters of several candidate pathways
in bladder carcinoma cell lines and normal proliferating uroepithelial cells. Luciferase
reporter plasmids whose activity was specifically dependent on either MAP kinases
(SREluc), AP-1 (APIluc), b-catenin/TCF (TOPluc), or E2F (E2Fluc) were transfected
into one of six well-characterized bladder carcinoma cell lines (VMCub1, VMCub2,
HT1376, SD, 5637, SW1710) or into normal uroepithelial cells in primary culture
stimulated to proliferation with EGF and cholera toxin. Luciferase activities were
corrected for transfection efficiency and the measured activities were related to those
of standard plasmids with constant constitutive activities. Controls included reporter
plasmids with mutations of the specific binding sites (e.g., FLOPluc with a mutated
binding site for TCF) and cotransfection of specific activators (e.g., a plasmid
expressing constitutively active MEKK to activate SREluc and AP1luc). 
Surprisingly, the activities of SREluc and AP1luc reflecting MAP kinase pathway
activity were 3–20 fold lower in the bladder carcinoma cell lines than in several inde-
pendent cultures of normal uroepithelial cells, with the highest activity observed in
HT1376. Modulation of SREluc activity by EGF or serum in the carcinoma cell lines
was threefold at most. Cotransfection of MEKK led to an up to 100fold induction
which was most pronounced in the cell lines with the lowest basal activity. TOPluc did
not show higher activities than FLOPluc in the bladder carcinoma cell lines indicating
inactivity or even repression of the TCF-dependent branch of the Wnt signaling
pathway. In comparison to normal uroepithelial cells, the E2F-dependent plasmid
yielded significantly increased activity in HT1376 and 5637 which lack Rb protein,
but was only up to 2fold more active in the other cell lines, even though three of them
lack p16INK4A. This result was confirmed with two other E2F-dependent promoters
from the c-MYC and the cyclin E genes. 
The pattern of proliferation signals in the nucleus of the investigated bladder carci-
noma cell lines differed significantly from that observed in normal proliferating
uroepithelial cells. In particular, at least two pathways often thought to be responsible
for increased proliferation of tumour cells were not constitutively activated. As a clin-
ical corollary, it is anticipated that some bladder carcinomas may not respond well to
therapy using inhibition of these pathways. 24 Oral presentations
7.1
EXPRESSION IN UVW GLIOMA CELLS OF THE
NORADRENALINE TRANSPORTER GENE, DRIVEN BY THE
TELOMERASE RNA PROMOTER, INDUCES ACTIVE UPTAKE OF
[131I]MIBG AND CLONOGENIC CELL KILL M Boyd1, RJ Mairs1, McCluskey,
S Carlin1, SH Cunningham1, L Wilson1, A Livingstone1, M Quigg, WN Keith2,
Depts of 1Radiation & 2Medical Oncolgy, CRC Beatson Labs, Glasgow G61
IBD, UK 
Aims Targeted radiotherapy is the selective irradiation of tumour cells by radionu-
clides conjugated to tumour-seeking molecules. One promising agent is radiolabelled
meta-iodobenzylguanidine (MIBG) which is actively taken up via the noradrenaline
transporter (NAT), in neuroendocrine derived tumours. Our aim is to apply MIBG
targeting to a wider range of tumours via transfection of the NAT transgene and to
utilise the human telomerase RNA promoter (hTERC) to achieve tumour specific
transgene expression. 
Methods NAT cDNA was cloned under the control of the strong ubiquitous RSV
or the human telomerase RNA promoter (hTERC). NAT expression was determined
by [131I]MIBG uptake and cell kill assessed by clonogenic assay. The capacity for
upregulation of hTERC by external beam radiation was examined. 
Results and Conclusions UVW cells transfected with RSV/NAT and
hTERC/NAT, were endowed with the capacity for active uptake of [131I] MIBG. NAT
gene expression via the hTERC promoter resulted in uptake levels 70% of that
achieved with the RSV promoter. We observed dose dependant cell kill of clonogens
derived from [131I]MIBG treated spheroids, with total clonogen sterilisation after
administration of 5 and 7MBq/ml [131I]MIBG to RSV/NAT/UVW and hTERC/-
NAT/UVW spheroids respectively. hTERC promoter activity was upregulated 2-fold
by administration of 2 Gy gamma irradiation. 
These data suggest that hTERC is a strong promoter which has potential for
tumour specific cancer gene therapy. 
7.2
TRANSFECTION OF THE SODIUM IODIDE SYMPORTER GENE
FOR TUMOUR TARGETING WITH RADIOIODINE AND
[211At]RADIOASTATINE RJ Mairs1, S Carlin1, M Boyd1, SH Cunningham1, 
P Welsh2 and MR Zalutsky2, 1Dept of Radiation Oncology, CRC Beatson
Labs, Glasgow G61 1BD, Scotland, 2Radiology Dept, Duke University,
Durham, NC, USA 
Objectives Targeted radionuclide therapy entails the delivery of radionuclides speci-
fically to tumour cells. The most successful example is the treatment of disseminated
thyroid carcinoma using sodium radioiodide (Na131I), which is actively concentrated
by the sodium (Na) iodide (I) symporter (NIS). Our aim was to transfect the NIS gene
into tumour cells and to assess uptake and cell kill using the radiohalogens [131I]iodine
and [211At]astatine. 
Methods The human NIS gene was cloned into a plasmid vector for transfer into
human glioma cells (UVW). Uptake and retention of 131I and 211 At were assessed by
gamma counting after precipitation. Cell kill was determined in monolayer and
spheroid culture by clonogenic assay. 
Results Compared with UVW cells transfected with an irrelevant gene, NIS gene
transfected cells exhibited 60-fold enhancement of uptake of 131I and 211At. The half
time of retention of both radiohalides was 3 minutes. Uptake of 211At was completely
blocked by incubation at 4˚C and by treatment with 100 mM perchlorate. We
observed a dose response relationship between radioactivity concentrations of 131I and
clonogenic survival: 2% of clonogens survived treatment with 4MBq/ml, at which
concentrations the survival of controls was > 90%. 
Conclusions The inhibition profile demonstrated that active uptake by the trans-
fectants of both 131I and 211At was mediated by NIS. Clonogenic survival assays
confirmed the efficacy of 131I and demonstrated the potential of 131I for the treatment of
cancers of non-thyroidal origin. Our preliminary results also suggest the possibility of
NIS-based gene therapy for tumour targeting using the highly radiotoxic halogen
[211At]astatine. 
7.3
TREATMENT OF LYMPHOMA WITH IRRADIATION AND ANTI-
CD40 CAN INDUCE LONG-TERM PROTECTION VIA A CD8 T-
CELL DEPENDENT PATHWAY J Honeychurch1, M Glennie2, P Johnson1, 
T Illidge1, 1CRC Dept. of Oncology and 2Tenovus Research Laboratory,
Cancer Sciences Division, Southampton General Hospital, Southampton
University, SO16 6YD, UK 
Here we describe the use of in vivo models to determine the efficacy of treating B-cell
lymphoma with monoclonal antibodies (mAb) and irradiation. Two syngeneic murine
lymphoma models have been employed (A31 and BCL1), treated with combination
total body irradiation (TBI) (1–6 Gy) and anti-CD40 mAb. When used as single ther-
apeutic modalities, neither the TBI or mAb alone were able to extend survival by
more than seven days over control cohorts. However, when TBI and anti-CD40 were
used in combination, a clear radiation dose-response was seen with 100% animals
treated with 6 Gy becoming long-term disease free survivors (> 100 days), versus
80% which received 5 Gy, and median survivals at lower doses were 42 days (4 Gy),
37 days (3 Gy), and 25 days (0–2 Gy) (P < 0.01). 
Tracking experiments were conducted to follow tumour expansion and immuno-
logical response in vivo. Flow cytometric analysis revealed that in animals showing
long-term protection there was a dramatic expansion of CD8 T-cells (between 3 and
10-fold), compared with those animals that received TBI alone. Simultaneous with
this response, was a dramatic decrease in the number of tumour cells. When the ratio
of T-cells to tumour cells was calculated, we observed a highly significant 12–16-fold
greater ratio of CD8 T-cells to tumour cells in the long-term survivors treated with
anti-CD40 plus higher doses of TBI, compared to those treated with mAb or TBI
alone. In order to confirm that the CD8 T-cells were responsible for the observed
protection, therapies were conducted in mice depleted of T-cells by anti-CD8 mAb.
Here the degree of protection provided by the combination treatment was almost
completely abrogated. This response is specific to TBI in combination with anti-
CD40, as mAb to other targets, for example MHC class II, do not generate an
immunological response, or provide protection. 
We have demonstrated for the first time that irradiation and anti-CD40 mAb can
have an additive therapeutic effect in vivo, and that this effect is dependent upon CD8
T-cells. These observations may have important implications for the application of
RIT in the clinic. 
7.4
CELL-BASED VECTOR DELIVERY FOR CANCER GENE
THERAPY JD Chester1,5, RM Diaz5, A Ruchatz5, H Chong5, 
T Clackson2, FL Cosset3, L Alvarez-Vallina4,5, SJ Russell5, KJ Harrington5,
RG Vile5, 1ICRF Clinical Centre, St James’ Hospital, Leeds, UK; 2Ariad
Pharmaceuticals, Cambridge, MA, USA; 3INSERM U412, Lyon, France;
4Hospital Universitario ClÍnica Puerta de Hierro, Madrid, Spain; 5Molecular
Medicine Program, Mayo Foundation, Rochester, MN, USA 
Progress towards systemic delivery of viral and non-viral vectors to treat tumours in
vivo has been hindered by the limited efficiency and specificity of delivery of thera-
peutic genes to the tumour site. 
We propose a cell-based strategy for delivery of viral vectors for tumour therapy.
This strategy exploits the natural tissue tropisms of certain cells. For example lympho-
cytes containing a gene therapy vector might be allowed to ‘home in’ on areas of
inflammation; macrophages to areas of hypoxia; and endothelial stem cells to areas of
active angiogenesis. To provide localised, specific expression from vectors delivered
in this way, we have generated a novel, retroviral gene therapy vector, which allows
bi-modal (inducible and tissue-specific) regulation of transcription. Production of a
retroviral genome from a plasmid vector is placed under inducible control of the
rapamycin dimerisation system (Rivera et al, 1996 Nat Med 2: 1028). A second level
of transcriptional regulation is provided by the presence of the tissue-specific carcino-
embryonic antigen (CEA) promoter in the U3 region of the viral genome. In this way,
delivery/producer cells should generate viral particles only when induced to do so by
oral administration of rapamycin, after they reach the tumour. Viral particles released
in this way will then be able to infect surrounding, dividing cells. However, due to the
presence of the tissue-specific CEA promoter, expression of any therapeutic gene
contained within the vector should only occur in colorectal cells. 
As initial proof-of-principle, we show that human T cells (Jurkat), murine
macrophages or murine HSC transduced with this vector can generate recombinant
retroviral particles which subsequently express a retrovirally-encoded reporter (GFP)
gene only in CEA-positive colorectal tumour cells (SW620, SW116, LoVo, HCT116)
but not in a range of non-colorectal (HeLa, Mel624, HT1080) cells. Induction of
vector production is totally dependent upon rapamycin and cell type-specificity is
maintained in mixed cultures of colo-rectal and non-colorectal cells. To date, titres in
the range of 104–105/ml can be released from the cell vehicles. 
In summary, we are developing cells and vectors which allow in situ production of
vector at a tumour site. Exploiting the capacity of certain cell types to target particular
tumour sites should increase the effective vector dose within tumours. 
Part of this work has been supported by the McElwain Scholarship (awarded to
JDC) from the Association of Cancer Physicians, UK. Oral presentations 25
7.5
A SINGLE PRE-OPERATIVE INJECTION OF Dl1502
ATTENUATED ADENOVIRUS IN INTRA-ORAL SQUAMOUS
CARCINOMA. Morley SE, 1Brown R, 2Kirn D, 1Kaye S, and Soutar DS, 
Dept of Plastic Surgery, Canniesburn Hospital, Glasgow, 1Dept of Medical
Oncology, Glasgow University. 2Onyx Pharmaceuticals, Richmond, California 
Objectives dl 1502 (previously named Onyx-015) is a gene-deleted adenovirus
designed to kill cancer cells that lack function of the tumour suppresser p53 protein.
The virus should trigger apoptosis in healthy cells with functional p53 thereby
preventing a productive infection and limiting tissue damage in non-malignant tissues.
Despite previous clinical studies, little is known about spread and replication of the
virus within a tumour mass or harmful effects on normal tissue. A study was devised
investigating a pre-operative intra-tumoural and normal tissue injection in patients
with operable intra-oral squamous carcinoma (SCC) to assess the p53 selectivity of
the virus; to determine how it spread throughout tissues and to assess any damage to
healthy tissues. 
Methods 15 patients with intra-oral SCC were assigned to receive an injection of
dl 1502 into each hemi-tumour 1, 3 or 14 days prior to resection, with the other half
acting as a control, and an injection of dl1502 into adjacent normal tissue. P53 status
of tumours was determined by gene sequencing. Following resection each hemi-
tumour and the normal tissue was assayed for viral presence using in-situ hybridisa-
tion and immunohistochemisry, which was also performed to determine p21 and p53
expression and apoptosis levels. 
Results 15 patients have been treated to date with no apparent damage to the
injected normal tissue. Evidence of viral presence was found in only 3 out of 15
samples of normal tissue. Virus has been detected preferentially in p53 mutant tumour
tissue with 8 out of 11 p53 mutant samples positive. Gross tumour destruction was not
noted in any tumour samples but microscopic cytolysis was found in 5 tumours, all
with mutant p53. p53 and p21 expression did not differ significantly between virus
injected and control tumour samples. Apoptosis was noted to be higher in virus
injected normal tissue than in tumour samples indicating that the virus could trigger
apoptosis in cells where p53 was functional. 
Conclusion The dl1502 adenovirus can be detected preferentially in p53 negative
tumour tissues following direct intra-tumoural injection. Following injection into
normal tissue the virus does not cause tissue destruction but does trigger raised apop-
tosis levels, as would be predicted by its proposed mechanism of action. This supports
its role as a potential treatment for p53 defective tumours. As p53 is dysfunctional in
at least 60% of human solid tumours the virus could potentially be useful in a wide
range of human malignancy. 
7.6
A PHASE II STUDY OF A GENE-MODIFIED VACCINIA VIRUS
EXPRESSING MUCI AND IL-2 (TG1031) IN PATIENTS WITH
METASTATIC BREAST CANCER TA Plunkett, E Windmill, RB Acres1, 
1J Taylor-Papadimitriou, DW Miles, ICRF Breast Cancer Biology Group,
Guy’s Hospital, UK, 1Transgene, Strasbourg, France 
The overexpression and aberrant glycosylation of MUC1 in human breast cancer
results in the exposure of novel peptide epitopes and has made it a potential target for
tumour immunotherapy. TG1031 is an attenuated recombinant vaccinia virus (VV)
encoding both human MUC1 and the cytokine interleukin-2 (IL-2). VV was selected
as the vector because of its well-documented safety profile. The VV was attenuated by
both the removal of the thymidine kinase gene and by expression of IL-2, thereby
minimising the risk of infection in potentially immunocompromised patients. 
A single dose phase I study confirmed the tolerability and safety of TG1031, and
no viral shedding was observed. An open-label randomised phase II study was
designed to evaluate the anti-tumour and immunological activity of repeated adminis-
tration of TG1031 to patients with MUC1-positive metastatic breast cancer. Patients
received either 5 ´ 106 or 5 ´ 107 PFU by intramuscular injection at 3 week intervals
for 4 cycles, and at 6 week intervals thereafter until disease progression. Twenty-five
of 31 patients (85%) had already received chemotherapy for metastatic disease.
Common toxicities from TG1031 included injection site reactions (20%) and transient
pyrexia (20%). Two partial responses were observed (1 at each dose level; 2/3, 6%),
and 15 patients (48%) had stable disease ³4 weeks. IgG titres to VV increased in
29/30 patients tested but no significant humoral responses to the tandem repeat
sequence of MUCI were demonstrated. Similarly, proliferative responses to VV were
demonstrated, but there was no reactivity against the tandem repeat sequence of
MUC1. 
Conclusion Repeated administration of TG1031 was feasible and non-toxic.
Although some anti-tumour activity was documented, there was no evidence of a
humoral or cellular response to the tandem repeat sequence of MUC1. Further studies
with less immunogenic vectors and immunological studies of regions outside the
tandem repeat of MUC1 are proposed. 
7.7
TARGETING DRUGS TO THE LIVER: CLINICAL EVALUATION OF
POLYMER-BOUND DOXORUBICIN FOR THE TREATMENT OF
LIVER CANCER DH Palmer1, LW Seymour1, DR Ferry1, SA Hussain1, 
S Hesslewood2, PJ Julyan3, R Poyner3, J Doran1, AM Young1, S Burtles4, & 
DJ Kerr1 on behalf of the CRC Phase I/II Clinical Trials Committee, 
1CRC Institute for Cancer Studies, University of Birmingham, B15 2TA, 2Dept of
Physics and Nuclear Medicine, City Hospital NHS Trust, Birmingham, B18 7QH,
3Dept of Nuclear Medicine, Queen Elizabeth Hospital, University Hospital
Birmingham NHS Trust, B15 2TH 4Cancer Research Campaign Drug
Development Office, Cambridge Terrace, Regent’s Park, London, NW1 4JL, UK 
Purpose The anticancer agent doxorubicin has been targeted to the hepatic asialoglyco-
protein receptor (ASGPR) by linkage to N-(2-hydroxypropyl)methacrylamide copoly-
mers bearing galactosamine. Here we report a phase I clinical and pharmacokinetic
study of galactosamine-targeted poly HPNA-doxorubicin (known as PK2). 
Method Patients with primary or secondary liver cancer for whom conventional treatment
options had been exhausted were enrolled. Patients had no previous exposure to doxorubicin. 
Three objectives were addressed: (i) to define toxicity associated with intravenous
infusion of PK2, (ii) to determine efficiency of hepatic targeting using radio-imaging
with 123I-PK2, (iii) to assess cytotoxic efficacy of PK2. 
Results Thirty-one patients were recruited. Median age was 56 (range 19–76), 20 male,
11 female. Patients were treated in cohorts of three at a starting dose of 20 mg/m2 (doxoru-
bicin-equivalent) to a maximum tolerated dose of 160 mg/m2. Dose-limiting toxicity
comprised grade 3 fatigue, grade 3 mucositis, and grade 4 neutropaenia (patients 10–12). A
further nineteen patients were treated with 120 mg/m2. Side effects at this dose were toler-
able myelosuppression, alopecia, fatigue and mucositis. 
Radio-imaging confirmed significant targeting of PK2 to liver. Superimposition of
SPECT and CT scans showed that the majority of radioactive polymer was associated
with normal liver, with lower accumulations within hepatic tumour although this still
represents substantially higher intratumoural levels of doxorubicin than expected
following intravenous administration of non polymer-bound drug. 
Of twenty-three patients with primary hepatocellular carcinoma, three achieved partial
response and a further eleven had stable disease as demonstrated on sequential CT scans. 
Conclusions These results indicate that galactosamine-targeted polymer conjugates
can be selectively delivered to the liver following intravenous infusion. The MTD of
PK2 was 160 mg/m2. The recommended dose for future trials is 120 mg/m2, significantly
higher than the conventional dose of non polymer-bound doxorubicin. Although doxoru-
bicin has minimal clinical activity against hepatoma, since most cytotoxic drugs have
steep dose-response curves, the advantage obtained by generating significantly higher
tumoural drug concentrations with the polymer make it worthwhile investigating in
phase II efficacy studies. 
7.8
NEW THALIDOMIDE ANALOGUES; ANTI-CANCER, ANTI-
ANGIOGENIC AND IMMUNOSTIMULATORY. A Dalgleish1, 
J Marriott1, A Czajka1, I Clarke1, K Dredge1, G Muller2, D Stirling2, 1Oncology
Department, St George’s Hospital Medical School, London SW17 0RE,
2Celgene, Warren, NJ, USA 
Thalidomide has been shown to be clinically active in a wide variety of clinical condi-
tions including some tumours such as multiple myeloma (MM). In order to enhance
the known anti-angiogenic properties of Thalidomide and to avoid its major side
effect, a number of analogues have been developed. These fall into two major
subgroups namely selective cytokine inhibitors which are phosphodiesterase type IV
(PDE4) inhibitors and co-stimulatory immunomodulators. Prior to further testing, all
analogues studied were shown not to induce the embryological changes induced by
Thalidomide. Using rat aorta and human endothelial cell assays, we have been able to
demonstrate that a number of analogues from both groups have marked anti-angio-
genic activity. In addition, some of these molecules are strongly immunostimulatory,
inducing lymphocyte proliferation, IL-2 production and inhibition of TNF receptor 2. 
We have now shown that more recent analogues can induce tumour cell cycle
arrest and apoptosis by a caspase independent mechanism with down regulation of
Bcl-XL expression in pancreatic, colorectal and prostate cell lines. Two of these
analogues have now entered clinical trials in patients with MM, melanoma, pancreas
and renal cancers. Thalidomide has provided the framework for a series of drugs that
may have a major impact on clinical cancer treatment over the next decade. 
REFERENCES 
Marriott JB, Muller G, Dalgleish AG. Thalidomide as an emerging
immunotherapeutic agent. Immunology Today 1999; 20(12): 538–540 
Marriott JB, Westby M, Cookson S, Guchian M, Goodbourn S, Muller G, Shire MG,
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potent inhibitor of activation–Induced TNF alpha production. J Immunol
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Marriott JB et al. Immunomodulatory thalidomide analogues strongly inhibit the
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8.1
A MULTICENTRE PHASE I GENE THERAPY CLINICAL TRIAL
INVOLVING INTRAPERITONEAL ADMINISTRATION OF E1A-
LIPID COMPLEX IN PATIENTS WITH EPITHELIAL OVERIAN CANCER
OVEREXPRESSING HER-2/neu S Madhusudan1, N Bates1, E Flanagan1,
Charnock FMC1, M Gore2, DPJ Barton3, . Harper4, Chris Karapetis4,
Desmond Yip4, M Seckl5, H Thomas6, R Lechler7, N Lemoine7, M Pignatelli8,
TS Ganesan1. Oxford Radcliffe Hospitals1, Oxford, Royal Marsden Hospital2,
St. George’s Hospital3, Guy’s Hospital4, Charring Cross Hospital5,
Hammersmith Hospital7, London, Royal Surrey County Hospital6, Guildford,
Bristol Royal Infirmary8, Bristol, UK 
HER-2/neu proto-oncogene product, a transmembrane receptor tyrosine kinase, is
over-expressed in 10%–30% of ovarian carcinomas and is associated with a poor
prognosis. The E1A gene product of Adenovirus type 5 down regulates HER-2/neu
over-expression, causing regression of tumours in animal models. Intraperitoneal
administration of E1A-lipid complex is a novel gene therapy in ovarian cancer. The
primary objectives of the study were to demonstrate E1A gene transduction into
malignant cells after intraperitoneal administration of E1A-lipid complex, to assess
HER-2/neu down regulation and to determine the maximum tolerated dose of E1A-
lipid complex. Main inclusion criteria included performance status 0–3, relapse
following first line therapy, tumour positive for HER-2/neu over expression (i.e 
³ 20% of cells and the intensity of reaction on immunohistochemistry), no known
peritoneal loculation, normal renal, liver and coagulation profiles. Successive cohorts
of at least 3 patients received ascending doses of E1A-lipid complex (1.8, 3.6, 7.2,
10.8, 14.4 mg DNA/m2), to a maximum of 6 courses. Each course of therapy consisted
of weekly intraperitoncal administration for 3 weeks followed by 1 week of rest.
Peritoneal fluid was sampled at baseline and twice monthly for cellularity, cytology,
markers (Ca 125), and biological activity in target tumour cells (E1A transduction
assessed at DNA, RNA and protein levels and HER-2/neu by immunohistochemistry).
A total of 15 patients were recruited (stage III-8 and stage IV-7), 14 of whom were
evaluable. Median age was 57 years. Prior treatment was with platinum (80%) and
taxol (53%). Patients received 1.8 mg DNA/m2 (3), 3.6 mg DNA/m2 (4) and 7.2 mg
DNA/m2 (8). One patient completed six courses of therapy; all others did not due to
adverse events or disease progression. E1A gene transfer and expression in malignant
cells was seen in all patients (100%). Two patients (18%) had HER-2/neu down regu-
lation. There was no correlation between dose, E1A gene expression levels 
HER-2/neu expression levels, CA 125 levels nor tumour measurements. Adverse
events with intraperitoneal catheter included infection and catheter blockage. Severe
abdominal pain was dose-dependent and near dose-limiting toxicity was achieved at
7.2 mgs DNA/m2. Intraperitoneal E1A-lipid complex gene therapy is feasible and
safe. Clinical benefit will be assessed in future trials. 
8.2
TUMOUR VASCULARITY ASSESSED USING DOPPLER
ULTRASOUND PREDICTS THE RISK OF RESISTANCE TO
METHOTREXATE CHEMOTHERAPY IN GESTATIONAL TROPHOBLASTIC
TUMOURS R Agarwal1, S Strickland1, IA McNeish1, M Foskett1, D Patel2, 
J Boultbee2, ES Newlands1, MJ Seckl1, 1Dept of Medical Oncology and 2Dept
of Radiology, Charing Cross Hospital, London W6 8RF, UK 
Tumour angiogenesis determined histopathologically is an adverse prognostic factor
in several cancers. To assess tumour angiogenesis in vivo in patients with gestational
trophoblastic tumors (GTT), we used Doppler ultrasound to measure the uterine artery
pulsatility index (UAPI), and evaluated whether UAPI could provide independent
prognostic information on the risk of resistance to methotrexate chemotherapy (MTX-
R). 
All patients treated for GTT between March 1994 and January 1999 had their
records reviewed to determine their pre-treatment Charing Cross Hospital prognostic
score (CXH-PS), uterine volume, UAPI, number of metastases and human chorionic
gonadotrophin (hCG) concentration. 164 patients were included in the study, 47 of
whom subsequently developed MTX-R. 
UAPI, hCG, uterine volume, presence of metastases, and the overall CXH prog-
nostic score were all predictive of MTX-R on univariate analysis. UAPI remained an
independent predictor of MTX-R after multivariate analysis. The odds ratio for the
risk of MTX-R in patients with a UAPI≤ 1 compared to those with a UAPI>1 was
2.32 (95% CI 1.14–4.7, P = 0.02), and after adjustment for the CXH prognostic score
was 2.68 (95% CI 1.25–5.74, P = 0.01). 
UAPI, as an indirect in vivo measure of tumour angiogenesis in GTT, is an inde-
pendent predictor of response to chemotherapy. 
8.3
AUTOLOGOUS MUC-1 PULSED DENDRITIC CELLS ARE A
SAFE, FEASIBLE TREATMENT APPROACH IN PATIENTS WITH
CANCER AND ARE ASSOCIATED WITH CELLULAR IMMUNE
RESPONSES F Nussey1, M Waterfall1, K Samuel2, A Atkinson2, R Leonard1,
M Turner1,2, 1University of Edinburgh, Dept. of Oncology, Western General
Hospital, EH4 2XU, 2Scottish National Blood Transfusion Service, Cellular
Therapeutics Group, John Hughes Bennett Laboratories, Western General
Hospital, Edinburgh, UK 
Exploitation of the immune system in patients cancer represents a promising treatment
approach. Dendritic cells (DC) are professional antigen presenting cells which are
capable of inducing MHC restricted antigen specific CD4 and CD8 T cells in vitro when
pulsed with tumor antigens. The function of DC in patients with malignancy is deficient
and re-administration of ex-vivo cultured DC may reverse this. MUC-1 is a trans-
membrane glycoprotein which is aberrantly glycosylated in a number of human cancers
such that an occult epitope is exposed which provides an immunotherapeutic target. 
A phase 1 clinical trial of MUC-1 pulsed DC began in July 1999. 12 patients with
breast, ovarian, colorectal and oesophageal cancer have been treated. 4 patients
remain on follow up. Mononuclear cells were obtained from a peripheral blood dona-
tion or leucapheresis and adherent monocytes were cultured in GM-CSF and IL4 to
obtain DC. These were then pulsed with a liposomal preparation of a 25-mer peptide
from MUC-1 (BLP-25, Biomira Inc) and re-administered by subcutaneous injection.
DC were defined as cells expressing CD1a. Patients received between 0.075 ´ 106 and
1.0 ´ 106 DC per kg body weight in one or two doses. They were followed up for
toxicity, immune response and clinical effects at days 1, 7, 14, 28 and 90. 
11 patients are currently assessable being more than 28 days from treatment.
Minor, self limiting grade 1 toxicitites were reported by 8 patients and included
fatigue and pain at the injection site. Grade 2 fatigue was seen in 2, myalgia in 1 and
anaemia in 1. No grade 3 or 4 toxicities were seen. 4 patients had stable disease radio-
logically and clinically at 28 days, one after prior progression, but all had progressed
by 3 months. Immunological effects – a small but significant increase occurred in
proliferative response to the MUC-1 antigen in patients over time compared with
controls (n = 6). There was an increase in response to repeated skin testing with PPD,
a recall antigen, following the DC therapy (n = 9). Patients mean pre-treatment value
was 3.2 mm, post treatment 13 mm (P = 0.03, Students t test), compared to controls 
(n = 5), who showed no response to re-testing over the same time period (initial test
mean 17.6 mm, repeated test mean 23.6 mm, P = 0.13, Students t test). 
This phase 1 trial demonstrates a safe, feasible treatment approach with biological
effects in patients with a range of malignancies. Larger studies will be required to
show potential therapeutic benefit. This work is supported by a grant from the
Melville Trust for the Care and Cure of Cancer. 
8.4
RAISED PLASMA HOMOCYSTEINE LEVELS IN WOMEN WITH
METASTATIC BREAST CANCER, A Makris1, RJ Burcombe1, 
H Cladd1, JM Smith2, M Makris2, 1The Marie Curie Research Wing, Mount
Vernon Hospital, Northwood, UK and 2Sheffield Haemophilia and Thrombosis
Centre, Royal Hallamshire Hospital, Sheffield, UK 
It is well recognised that patients with malignancy have an increased risk of venous
thromboembolic disease. The pathophysiology of this association has not been
precisely defined. Hyperhomocysteinaemia has recently become established as one of
the commonest conditions associated with venous and arterial thrombosis. 
We examined the prevalence of hyperhomocysteinaemia in women with early and
advanced breast cancer. Three groups of women were studied: Group 1 – healthy
female controls (n = 21); Group 2 – early breast cancer (n = 30); and Group 3 –
metastatic breast cancer (n = 39). All samples were collected prior to chemotherapy in
the breast cancer patients. The homocysteine concentration was estimated in plasma
using the Abbott IMx immunoassay method. Samples were separated within 1 hour of
collection. 
The mean (SD) plasma homocysteine levels were Group 1 = 7.9 mmol/l (1.9),
Group 2 = 9.57 mmol/l (5.6) and Group 3 = 11.4 mmol/l (5.2). 35.9% of patients with
metastatic and 13.3% with early breast cancer had plasma homocysteine concentra-
tions above the upper limit of normal. Women with metastatic disease had signifi-
cantly higher plasma homocysteine concentrations compared to controls (P < 0.005)
or women with early breast cancer (P < 0.05). No difference was observed when
women with early breast cancer were compared to controls (P = 0.32). 
We conclude that hyperhomocysteinaemia is common in women with metastatic
breast cancer but was not observed in women with early disease where homocysteine
concentrations were similar to controls. This observation could explain the high rate
of venous thrombosis in women with metastatic breast cancer. Since hyperhomo-
cysteinemia is easily corrected with oral folic acid, a therapeutic trial of this drug as a
thromboprophylactic agent is warranted. Oral presentations 27
8.5
INTRA-OPERATIVE ASSESSMENT BY OPTICAL BIOPSY FOR
SENTINEL LYMPH NODE METASTASIS IN BREAST CANCER 
AC Lee1, CDO Pickard1, MRS Keshtgar2, SG Bown1, GM Briggs1, 
S Lakhani3, IJ Bigio4, PJ Ell5, 1National Medical Laser Centre, 2Department of
Surgery, 3Department of Histopathology, 5Institute of Nuclear Medicine, Royal
Free and University College Medical School, University College London,
Charles Bell House, 67–73 Riding House Street, London W1W 7EJ UK,
4Department of Biomedical Engineering, University of Boston, USA 
Aims The histological status of the axillary lymph nodes remains one of the most
important prognostic indicators in breast cancer patients. It was the aim of this study
to evaluate the accuracy of optical biopsy1 (OB) as an intraoperative diagnostic tool to
determine the histological status of the sentinel lymph node (SLN) in patients with
invasive breast cancer. 
Procedures Since October 1998, A total of 51 patients had been enrolled in the
second phase of this study. The median age of the patients was 52 years (range, 34 to
88 years). After harvesting, the SLN was bivalved. Optical spectra were acquired
using a clean probe from a number of representative points on the cut surface. The
SLN was sent for histopathology. 
Results A total of 77 SLN were biopsied from 51 patients (1.5 SLN per patient).
The sensitivity of this technique was 87.1%; the specificity was 85.2%. 
Significance Current intra-operative methods of assessing SLN for metastasis in
breast cancer are fresh frozen section and imprint cytology. These techniques are
operator dependent and time consuming. OB has the potential to provide an instant,
non-operator dependent assessment of sentinel nodes. 
Conclusion OB has the potential to provide instant and non-operator dependent
intra-operative analysis of SLN in patients with breast cancer, which will enable the
surgeon to decide on performing axillary lymph node dissection at the time of initial
surgery. Sensitivity and specificity should increase as the database of correlated
biopsies increase in size. 
1. Bigio IJ, Bown SG and Briggs G et al. (2000) J. Biomedical Optics 5(2): 221 
8.6
EVIDENCE THAT THE CARDIOVASCULAR TOXICITY OF
ANDROGEN DEPRIVATION THERAPY FOR PROSTATE
CANCER MIGHT COMPROMISE A SURVIVAL BENEFIT MD Mason1, 
JC Smith1, S Bennett1, HG Kynaston1, M Parmar2, JS Davies1, 1University of
Wales College of Medicine, Heath Park, Cardiff CF14 4XW and 2MRC
Clinical Trials Unit, London NW1 2DA, UK 
One of the greatest surprises in the Prostate Cancer Trialists’ Group meta-analysis of
immediate versus deferred hormone therapy was that a clear benefit for immediate
therapy in terms of a reduction in prostate cancer-specific mortality did not translate
into an overall survival benefit. We reasoned that this might be due to an, as yet,
undocumented detrimental effect of androgen deprivation on survival, and that cardio-
vascular morbidity was a likely mechanism. Were this true, amelioration of this effect
might yield survival benefits for early androgen deprivation, at best to an extent
comparable to the benefits of adjuvant therapy for breast cancer. In order to test this,
we studied the effects of androgen deprivation therapy on large artery stiffness in 22
prostate cancer patients (mean age 67±8 yrs) over a 6 month period. Arterial stiffness
was assessed using Pulse Wave Analysis, a technique that measures peripheral arterial
pressure waveforms and generates corresponding central aortic waveforms. This
allows determination of the augmentation of central pressure resulting from wave
reflection and the Augmentation Index, a measure of large artery stiffness. Body
compositional changes were assessed using Bioelectrical Impedance Analysis.
Fasting lipids, glucose, insulin and testosterone were measured. Following a 3 month
treatment period, the Augmentation Index increased from 24 ± 6 (mean ± SD) at base-
line to 29 ± 9% (P = 0.003) despite no change in peripheral blood pressure. Timing of
wave reflection was reduced from 137 ± 7 to 129 ± 10 ms (P = 0.003). Fat mass
increased from 20.2 ± 9.4 to 21.9 ± 9.6 kg (P = 0.008) whilst lean body mass
decreased from 63.2 ± 6.8 to 61.5 ± 6.0 kg (P = 0.016). There were no changes in
lipids or glucose during treatment. Serum insulin rose from 11.8[5.6– 49.1]
(median[range]) to 15.1[7.3–83.2]mU/L at 1 month (P = 0.021) and to
19.3[0–85.0]mU/L by 3 months (P = 0.020). There was a correlation between the
changes in fat mass and insulin concentration over the 3 month period (r = 0.56, P =
0.013). In a sub-group of patients whose treatment was discontinued after 3 months,
the Augmentation Index decreased from 31±7 at 3 months to 29±5% by 6 months in
contrast to patients receiving continuing treatment in whom the Augmentation Index
remained elevated at 6 months compared with baseline (P = 0.043). These data
suggest that androgen deprivation results in large artery stiffening and reduced insulin
sensitivity, both established markers of increased cardiovascular risk. We are now
confirming these results further in a larger prospective study. 
8.7
RESTORATION OF OVARIAN FUNCTION AFTER
REIMPLANTATION OF AUTOLOGOUS CRYOPRESERVED
OVARIAN CORTICAL STRIPS (OCS) FOLLOWING HIGH DOSE
CHEMOTHERAPY FOR LYMPHOMA JA Radford1, DR Brison2, SA Russell2,
M Harris1, AJ Watson1, JA Clayton1, RG Gosden3, SM Shalet1, 
BA Lieberman2, 1Christie Hospital, Manchester, UK, 2St Mary’s Hospital,
Manchester, UK, 3McGill University, Montreal, Canada 
Since February 1996, 16 women (median age 24 years, range 17–36) have undergone
unilateral laparoscopic oophorectomy shortly before receiving high dose chemo-
therapy (HDCT) for lymphoma (n = 14) or acute lymphoblastic leukaemia (n = 2).
The surgical procedures were well tolerated and without complication. In each case
the cortex was stripped from the ovary en bloc, flattened, trimmed and cut into strips
(OCS) approximately 1 ´ 0.5 cm (median 7 OCS per ovary, range 5–10). Following
equilibration in cryoprotectant (1.5 molar DMSO), the OCS were placed in individual
vials, cooled in a programmable rate freezer with seeding at –9 ˚C and stored in liquid
nitrogen. Since HDCT 6 patients (pts) have died of disease and 10 are alive and
disease-free. One of the latter (now aged 39, received HDCT August 1998) opted for
reimplantation of OCS and hormone replacement therapy (HRT) was discontinued in
mid-November 1999. By assaying serum sex steroids, ovarian failure was confirmed
and laparoscopic reimplantation of 2 OCS was performed in March 2000. Each OCS
was removed from liquid nitrogen and kept at room temperature for 30 seconds before
being plunged into a 37˚C water bath for approximately 1 minute. DMSO was
removed by three, 5 minute rolling washes in 10 ml of Liebovitz medium. The OCS
were trimmed and then placed in sterile medium before being transferred to theatre
where 1 OCS was grafted onto the ovarian pedicle (oophorectomised side) and
another onto the remaining ovary (non-oophorectomised side). Seven months
following reimplantation of OCS (mid October 2000) the patient became free of hot
flushes and serum oestradiol became detectable. The LH and FSH have since fallen to
19 iu/L and 41 iu/L respectively (previously 84 iu/L and 110 iu/L). Pelvic ultrasonog-
raphy performed 22/11/2000 (oestradiol 352 pmol/L) showed an endometrial thick-
ness of 11 mm, a residual left ovary with an approximate volume of 2 mls containing
no follicles and to the right of the midline (oophorectomised side) a follicular structure
with an approximate volume of 6 mls and containing a dominant 2 cm follicle. On
29/11/00 (oestradiol 120 pmol/l) the left ovary remained small with no evidence of
any follicular development and the right sided cyst was no longer visible. The patient
subsequently menstruated. 
Although this is a preliminary report it appears that orthotopic reimplantation of
frozen thawed OCS is an effective technique for restoring ovarian function in women
treated with sterilising chemotherapy for lymphoma. 
8.8
FERTILITY AND QUALITY OF LIFE AFTER TREATMENT FOR
TESTICULAR CANCER RA Huddart1,2, A Norman1, C Moynihan2, 
D Coward2, J Nicholls2, G Jay2, M. Shahidi2, A Horwich1,2, D Dearnaley1,2,
The Royal Marsden Hospital1 and The Institute of Cancer Research2, Sutton,
Surrey, SM2 5PT, UK 
Modern treatments cure most testicular cancer patients so an important goal is to
minimise toxicity. We have undertaken a cross-sectional study to evaluate the quality
of life (Qol) of long term survivors of testicular cancer. 654 patients treated between
1982 and 1992 completed the EORTC Qly-C-30(QC30) questionnaire, the associated
testicular cancer specific module and a general health and fertility questionnaire.
Patients have been subdivided according to treatment received: orchidectomy either
alone (surveillance, S), with chemotherapy only (C), radiotherapy only (R), or both
chemotherapy and radiotherapy (C/RT). 
Only 221 (30%) patients reported attempting conception after treatment. When
attempted, the success rate was high with 178 (81%) reporting success. A further 12
patients (5.4%) were successful after infertility treatment but 43 (19%) were unsuc-
cessful, (with or without fertility treatment). There was a trend to lower success rate
after C (75%) (P = 0.133) compared to S (85%). 
Overall Qol was good with mean scores in the all domains of the QC30 in the
range of 83–95; equivalent to or in excess of both pre-treatment testicular patients and
normal population reference scores. 53% of patients reported anxiety regarding recur-
rence which was moderate/severe in 11% especially in patients receiving treatment 
(C 13%, C/RT 10%, RT 13%, S 5%). Treated patients also had a higher chance of
impaired social functioning (S 95, RT 92 (P = 0.24), C/RT 89 (P = 0.003), C 92 
(P = 0.056) ). 42% of patients reported difficulties with work or obtaining insurance
mortgages especially after C (S 37% C 46%). 18% felt their disease had affected their
relationship (especially after chemotherapy C 19% (P = 0.175), C/RT 26% 
(P = 0.022) v S 14%). 
Compared to S, patients after C were more likely to report tingling (P = 0.001),
pale cold hands (P = 0.001), ringing in the ears (P = 0.05); dyspnoea (P = 0.05) and
worries about fathering (P = 0.009) and in the C/RT upset about hair loss (P = 0.017)
and less interest in sex (P = 0.01). R alone was associated with reduced sexual
activity/enjoyment (P = 0.05) 
In summary the majority of long term survivors have a good quality of life. Most
patients retain their fertility but the risk of infertility is increased by chemotherapy.
However, patients can suffer from long term effects of treatment and psychosocial
sequelae including difficulties in obtaining insurance. 28 Oral presentations
9.1
ICON1: A RANDOMISED TRIAL OF IMMEDIATE PLATINUM-
BASED CHEMOTHERAPY AGAINST CHEMOTHERAPY
DELAYED UNTIL INDICATED IN WOMEN WITH OVARIAN CANCER 
D. Guthrie on behalf of the ICON Collaborators, MRC Clinical Trials Unit, 222
Euston Road, London NW1 2DA, UK 
Background A series of meta-analyses of randomised controlled trials raised the
question of whether adjuvant chemotherapy prolongs disease-free survival in women
with early stage epithelial ovarian cancer. 
Method We carried out an international, multicentre, randomised trial to compare
immediate platinum-based chemotherapy against chemotherapy delayed until indi-
cated, in women with ovarian cancer for whom doctors were uncertain if chemo-
therapy was required immediately after optimal primary surgery. 
Findings The first results will be presented at the EORTC/BGCS/UKCCCR/MRC
Collaborators’ Meeting on Gynaecological Cancer in April 2001, and therefore results
by treatment arm are not presented here. 447 patients were randomised from 91
centres in five countries; 241 to immediate treatment and 236 to delayed treatment.
The median age was 55 years with over 80% patients being FIGO stage 1. The major
histological cell types were serous (30%), mucinous (21%), endometrioid (21%) and
clear cell (14%). Differentiation of disease was classified as poor in 27% of patients,
intermediate in 41%, and well in 32% of patients. The patient characteristics were
similar in both treatment groups. With over 3 years median follow-up for survivors, it
was estimated that the 3 year progression-free survival was 78%, and overall survival
was 85%. 
It is hoped that the data from ICON1 and ACTION, a comparable trial launched by
the EORTC and run in synchrony with ICON1, can be combined. 
9.2
AIM HIGH – ADJUVANT INTERFERON IN MELANOMA (HIGH
RISK): NO CONFIRMATION YET THAT LOW DOSE
INTERFERON IS OF BENEFIT B W Hancock1, LA Turner1, K Wheatley2, 
G Harrison3, M Gore4, 1Weston Park Hospital, Sheffield, 2University of
Birmingham, 3University of Oxford, 4Royal Marsden Hospital, London, UK 
In the UK, the mortality rate from melanoma has doubled over the past 20 years. This
currently represents about 2% of all new cases of cancer and 1% of all cancer deaths1.
It has been shown that Interferon can be an effective palliative treatment in metastatic
melanoma. There is early evidence that treatment prolongs disease free survival and
may have an effect on overall survival2,3. The primary objective of this trial was to
determine the effects of Interferon alpha-2a with observation alone on overall survival
(OS) and recurrence-free survival (RFS) of patients with high risk malignant
melanoma. Secondary objectives were to study the interaction of Interferon alpha-2a
with age and sex, to document the side effects of long term administration of
Interferon and evaluate the economic implications to the health service should
Interferon prove effective in this group of patients. Between 3 October 1995 and 22
December 2000, a total of 674 patients were recruited from 37 centres in the UK. 337
patients were treated with Interferon alpha 2a 3 million units three times a week until
recurrence or for two years and 337 patients with observation alone. The arms of the
study were well balanced for age, sex and type of disease. 130 had a primary tumour
³ 4 mm Breslow thickness, 74 non-nodal superficial regional recurrence, 85 regional
lymph nodes resected at presentation and 385 regional lymph nodes resected at recur-
rence. Median follow up is 489 days (range 2–1885 days). The OS and RFS at four
years for all patients are 51(se3.0)% and 31(se2.6)% respectively. At four years there
was no significant difference in OS or RFS between the Interferon treated and control
arms (52 se4.0% vs 50 se4.4%, P = 1.0, and 33 se3.6% vs 29 se3.7%, P = 0.2, respec-
tively). Male sex (P = 0.04) and regional lymph node involvement (P = 0.002) were
statistically significant adverse features for OS. Subgroup analysis by age, sex and
disease has not yet shown any significant differences between Interferon treated and
control groups in either OS or RFS. Although preliminary meta-analysis showed a
statistically significant advantage for Interferon regardless of dose1, these preliminary
results from AIM HIGH do not yet confirm that extended duration low dose Interferon
is better than observation alone in the initial treatment of completely resected high risk
malignant melanoma. 
1. BW Hancock et al, Cancer Treatment Reviews 2000; 26: 81 
2. JM Kirkwood et al, J Clin Oncol 1996; 14: 7. 
3. JJ Grob et al, Lancet 1998; 351: 1905 
9.3
AN UPDATE REPORT ON THE MRC CR07 TRIAL D Sebag-
Montefiore on behalf of the MRC Colorectal Cancer Group and all
the CR07 participants. Cancer Division, MRC Clinical Trials Unit, 222 Euston
Road, London, UK 
This randomised trial compares 25 Gy pre-operative radiotherapy (RT) and selective
post-operative chemo-radiotherapy (45 Gy with synchronous 5 FU) in rectal cancer.
The trial opened in March 1998 and by the end of 2000 468 patients have been
accrued from 39 centres. Pre-treatment characteristics: male 70%, median age 70
years, distance from the tumour to the anal verge ≤12 cm 95%. 
Overall 59% of patients have had an anterior resection (AR) and 35% APER. Total
mesorectal excision (TME) surgery is not mandatory; however in the surgeon’s
opinion TME was intended and achieved in 90% of patients. Wound infections (16%),
non-healing perineum (12%) and chest infection (6%) are the main post-op morbidi-
ties. The anastomotic leak rate is 12% in patients undergoing an AR. 
Pathologists have reported the quality of the mesorectum on the specimen as
moderate or good in 84%, and that there were 5% pT1, 27% pT2, 61% pT3 and 7%
pT4. 84% of patients have had a complete resection at all margins. The median
number of lymph nodes sampled is 11, and 44% of patients have positive nodes. The
30-day post-op mortality is 3%. 
In the pre-op RT group 93% of patients have received 25 Gy/5f as prescribed.
Median time from randomisation to start of RT is 17 days and from end of radio-
therapy to surgery 5 days. In the post-op group the median time from randomisation to
surgery is 17 days, and 76% of the patients with a positive circumferential resection
margin (CRM) have received chemo-radiotherapy (a further 14% received RT alone). 
This trial will complement the results of the Dutch TME trial. 
9.4
IS SOME NEUTROPENIA GOOD FOR YOU? A SINGLE CENTER
EXPERIENCE OF ADJUVANT CMF IN 681 CASES OF EARLY
BREAST CANCER C Massie, G Kerr, RCF Leonard, DA Cameron 
On behalf of the Edinburgh Breast Group, Dept. Oncology and Breast
Surgery, WGH Edinburgh, UK 
An audit of women receiving adjuvant i.v. CMF chemotherapy for early stage breast
cancer identified over 700 patients who were treated between 1984 and 1998 by the
Edinburgh Breast Group. The casenotes of 681 patients have been reviewed and the
results are presented here. 
Results: Patients Because of changing selection policies more than 50% of
patients were treated during the last 3 years of the period. Median age was 47 years,
range 26–86 years. 13.2% of patients were aged 60 or over. The majority of patients
(67%) presented with clinical stage 2 disease. Median pathological tumour size was 2
cm. 68% had involved lymph nodes. 52.7% had high grade tumours. 
Results: Treatment 92.7% of patients completed 6 courses. 53% of patients had a
treatment delay and 8% a dose reduction due to toxicity. Dose reductions were twice
as common in patients aged 60 or over. Dose intensity ranged from 64% to 105% of
planned, median 85%. 549 patients received adjuvant radiotherapy, intercalated in
461. 
Results: Outcome There were no treatment related deaths and only 8 non breast
cancer deaths. 5 year cause specific survival was 71.5%; 68.7% for stage 2 disease.
Node negative patients had a 5 year cause specific survival of 85.9%. Heavy node
involvement was associated with poor survival. 46% of patients had grade 2 or 3
neutropenia which was associated with better long-term survival (80.5% at 5 years)
than grades 0, 1 or 4 (63.9% at 5 years), P = 0.0001. Grade 4 neutropenia did not lead
to a reduction in the number of treatment cycles. Patients who completed less than 4
courses of CMF had a significantly poorer survival than those who completed 4 or
more. Dose intensity appeared to have no effect on survival on univariate analysis. 
Conclusions In 681 reviewed cases the usual prognostic factors have been shown
to be associated with survival, outside the trial setting. The data suggest that achieving
a planned dose of CMF may be less important than planning an appropriate dose. Oral presentations 29
9.5
THE DEVELOPMENT OF CONSENSUS GUIDELINES FOR THE
MANAGEMENT OF CNS TUMOURS AS A RESULT OF A
NATIONAL SURVEY, WORKSHOP AND LITERATURE REVIEW 
G Gerrard1, K Dyker1, D Levy2, 1Dept. of Clinical Oncology, Cookridge,
Leeds, LS16 6QB, 2Weston Park Hospital, Sheffield, S10 2SJ, UK 
This study aimed to encourage collaboration amongst clinicians to ascertain regional
variations in treatment of CNS tumours before comparing inter-regional survival
figures in a national database. It also aimed to identify areas of treatment divergence
to stimulate debate, education and research and to create treatment guidelines. 
In November 1999, 54 clinical oncologists with an interest in primary CNS
tumours were sent a questionnaire regarding treatment issues for high and low grade
gliomas, meningiomas, pituitary adenomas, craniopharyngiomas, clivus chordomas,
brain metastases and temozolomide. 
In adult high-grade gliomas 78% (32/41) prescribe 60 Gy in 30 fractions over 6
weeks to young, good performance status patients. 66% (27/41) use CT planning.
95% (39/41) will treat patients over 70 years of age with the above regime if they are
of good performance status. If they are of poor performance status, 59% (24/41) use
30 Gy in 6 fractions over 2 weeks, but there are another 10 fractionation regimes 
used in the UK. 
97% (37/38) give craniospinal radiotherapy (CSRT) for high grade ependymomas
with CSF seeding and 61% (23/38) give it if no CSF seeding. 95% (36/39) would treat
lowgrade ependymomas with CSRT only if they had CSF seeding. 
For adult low-grade gliomas 72% (29/40) reserve treatment for clinical progres-
sion. 61% (25/41) give 54Gy in 30 fractions, with another 8 dose regimes in use in the
UK. 80% (33/41) treat benign meningiomas when indicated and 27% (11/40) give
radiotherapy to all atypical meningiomas. The commonest regime for all, including
malignant meningiomas is 54Gy in 30 fractions. 
In pituitary adenomas, 61% (25/41) use CT planning, 95% (39/41) giving 45Gy in
25 fractions. 95% (36/38) give radiotherapy for all incompletely excised cranio-
pharyngiomas, 69% (27/39) using CT planning. 78% (31/40) give 50 Gy in 30 frac-
tions. Proton treatment in Paris remains a controversial issue for clivus chordoma. 
In elderly, poor performance status patients 65% (24/37) treat some with whole
brain radiotherapy (WBRT) for brain metastases. 85% (35/41) would give WBRT
after resection of a solitary metastasis while 15% (6/41) would observe such patients. 
47% (19/40) give temozolamide as second line chemotherapy for recurrent
glioblastoma 40% (16/40) do not use it as there is no local funding or that they feel it
is no better than standard. 
9.5 Cont’d
For most CNS primaries, the majority of clinicians use similar regimes. The most
variation occurs in treatment of low- grade gliomas and elderly patients with high-
grade gliomas or brain metastases. The 54 participants will be informed of the results
and alternative regimes. The plan is to hold a workshop for discussion in order to
establish treatment guidelines. As the clinicians will be involved in this process, it
may encourage them to follow them, rather than have them imposed from above. 
9.6
EARLY RESULTS FROM THE UK HEAD AND NECK (UKHAN)
TRIAL: THE ROLE OF CHEMOTHERAPY IN PRIMARY
MANAGEMENT OF ADVANCED HEAD AND NECK CANCER JS Tobias1,
KM Monson1, J Glaholm2, RH MacDougall3, NK Gupta4, J Peto5, W Sawyer1,
J Houghton1 on behalf of the UKHAN Trial Group, 1CRC & UCL Cancer Trials
Centre, London NW1 2ND, 2Birmingham Oncology Centre, B15 2TH,
3Western General Infirmary, EH4 2XU, 4Christie Hospital, M20 4BX, 5ICR,
Sutton SM2 5NG, UK 
The UKHAN trial was designed as a large-scale single, pragmatic study investigating
the effect of adding chemotherapy to standard radical treatments for advanced head
and neck cancer. In order to make participation simple and ensure the results would be
widely applicable, outpatient chemotherapy (CT) protocols were chosen and all stan-
dard radiotherapy regiments (RT) were accepted, if approved by the working party. 
Patients presenting with UICC stage II, III & IV, squamous cell carcinoma of the
head and neck, who were suitable for RT to be given either as definitive radical
therapy or as post- operative treatment, were considered eligible and were approached
for consent. Patients with distant metastases were excluded. Non-surgical patients
were randomised to one of four arms: [1] RT alone.[2] RT with 2 courses of simulta-
neous CT administered days 1 & 14 of RT (SIM CT). [3] RT with 2 courses of subse-
quent CT administered 14 & 28 days after completion of RT (SUB CT). [4] RT with
both SIM CT & SUB CT (4 courses). Surgical patients requiring post-operative RT
were randomised to arms [1] & [2] only. Chemotherapy was given either as single
agent methotrexate or combination VBMF (vincristine, bleomycin, methotrexate, 
5-fluorouracil). Participating clinicians selected one of these regimens consistently
throughout the study period to all patients randomised to receive CT. 
Between 1990–2000 the trial accured 970 patients. At closure (July 2000) an
interim analysis was performed on 947 patients followed for at least 6 months (median
follow up 3.5 years). Clinical response was assessed at six months from randomisa-
tion; 73% of the SIM CT patients were disease-free compared with 69% of the RT
alone (non-significant). These patients also showed an improved event-free survival
(RR = 0.77, 95% CI 0.64–0.93) but no significant improvement in overall survival has
been demonstrated. No advantage has been shown for SIM CT in the surgical group 
(n = 243) or for patients randomised to SUB CT. Treatment related deaths occurred in
<2% of the total trial cohort. 
Early analysis of this large study suggests that non-platinum based chemotherapy
given simultaneously with standard RT confers a benefit to patients that is similar to
regimens using cisplatinum [see Pignon et al, Lancet 2000; 355: 949]. The regimens
used in UKHAN are inexpensive, well tolerated and widely acceptable, even in this
unfit group of patients with advanced head and neck cancer. 
9.7
FACTORS INFLUENCING THE USE OF THORACIC
RADIOTHERAPY (TRT) IN LUNG CANCER PATIENTS IN
SCOTLAND SC Erridge1, CS Thomson2, J Davidson2, RD Jones3, A Price1
on behalf of the Scottish Lung cancer Trials Group and Scottish Cancer
Therapy Network. 1Department of Oncology, Western General Hospital,
Edinburgh, 2Scottish Cancer Intelligence Unit, ISD Scotland, Edinburgh,
3Department of Oncology, Beatson Oncology Centre, Glasgow, UK 
Background Outcomes of patients with lung cancer in Scotland are poor in compar-
ison with other countries. 
Aims To determine the frequency of delivery of TRT to patients with lung cancer
in Scotland in 1995, and identify patient, disease and process variables affecting the
probability of receiving TRT. 
Methods Retrospective case note audit of all patients with lung cancer diagnosed
in Scotland in 1995. 
Results 1188 (30.8%) of 3855 patients diagnosed with lung cancer in Scotland in
1995 for whom the medical records could be traced received TRT. In those who did
not have small cell lung cancer, multivariate analysis indicated that diagnosis by a
lung cancer specialist, clinical extent of disease and microscopic verification of cancer
(all P < 0.0001) and age (P < 0.0005) were associated with an increased chance of
receiving TRT. There was also a wide variation between different Health Boards of
residence in the proportion of patients receiving TRT (P < 0.0001). There was no
association between the presence of local symptoms (cough, chest pain or haemo-
ptysis) and the probability of delivery of TRT. 
Of 351 patients with limited stage small cell lung cancer, 51 (14.5%) received
chemotherapy and TRT, and 19 (5.4%) chemotherapy and cranial irradiation. 
Conclusions TRT was delivered to fewer than one third of lung cancer patients in
Scotland in 1995. This is lower than in other international audits. The chance of
receiving TRT seemed to be associated with service issues rather than clinical need. 30 Oral presentations
9.8
ADJUVANT CHEMOTHERAPY IN EARLY BREAST CANCER:
WHAT DO PATIENTS UNDERSTAND? HE Innes1, C Holcombe2,
SM O’Reilly1, 1Clatterbridge Centre for Oncology, Merseyside CH63 4JY and
2Royal Liverpool University Hospital, Liverpool L7 8XP, UK 
Women with early breast cancer, even those with relatively low risk of recurrence, are
increasingly offered adjuvant chemotherapy. Patients are now being encouraged to
participate in the decision whether to have this treatment. To do this effectively they
need to be equipped with adequate information. This study explores the knowledge
and understanding of a group of women who have completed adjuvant chemotherapy.
We sent questionnaires to all 249 surviving patients who received adjuvant
chemotherapy between 6/95 and 6/99 at the Royal Liverpool University Hospital, all
treated by the same Medical Oncologist. All had been told the size, grade and no. of
involved nodes and had been advised of potential toxicity and likely prognosis. 
182 patients replied (73.1%), median age at diagnosis 47.5 (29 to 69). 22.5% were
educated beyond O level. Most patients felt that the level of information was ‘about
right’ regarding details of tumour (66.3%), treatment options (85.8%) and toxicity of
chemotherapy (84.5%). On risk of recurrence 48.8% felt that information was ‘about
right’, 50.6% ‘too little’ and 0.6% ‘too much’. 98 (53.8%) of respondents remembered
being told the risk of recurrence. 150 (82.4%) of respondents gave their own estimates
of their risk of recurrence at 5y. Patients’ estimates of recurrence risk and their expec-
tations of the benefits of chemotherapy were compared with their actual risks as deter-
mined by the Early Breast Cancer Trialists’ Collaborative Group overview. 
Age Nodal  Est. %   Actual % Est. % Actual %   
status risk of rec.  risk of rec. risk of  risk of
without  without rec. with  rec. with
chemo chemo chemo at   chemo 
at 5 y  at 5 y 5 y  at 5 y
(median) (median)
< 50 years Node –ve 50 34.1 15 24.7 
N = 100 Node +ve 60 58.1 20 42.9 
50–69 years Node –ve 42.5 29.7 12.5 23.4 
n = 50 Node +ve 62.5 46.7 20 40 
9.5 Cont’d
When asked what degree of benefit they felt would make chemotherapy worth-
while, >70% would accept a reduction in the risk of recurrence at 5 y of ≤ 5% (range
0.5–60%). In conclusion many patients overestimate both the baseline risk of recur-
rence and the potential benefit of chemotherapy. However, the majority of these
patients, all of whom have experienced adjuvant chemotherapy, would be prepared to
accept similar treatment again for relatively modest benefit. On the basis of these
results we have changed the written and verbal information given to patients in order
to improve understanding and enable more informed participation in the decision
making process. 
10.1
EPIGENETICS OF WILMS’ TUMOUR KW Brown, S Jackson, K
Moorwood, A Hancock, A Dallosso, KTA Malik, CLIC Research
Unit, Dept. Pathology & Microbiology, School of Medical Sciences, University
Walk, Bristol BS8 1TD, UK 
Despite intensive investigation of the genetics of Wilms’ tumour (WT), the molecular
pathogenesis of many cases remains unclear. We have therefore been studying novel
epigenetic changes in WT, to determine whether these are important in WT develop-
ment. Specifically, we have examined changes in DNA methylation that are known to
affect gene expression. In the WT 11p13 tumour suppressor gene WT1, we have
shown differential methylation of the antisense regulatory region (ARR) in normal
kidney, where one allele is hypermethylated and the other hypomethylated. In 80% of
WTs that lack 11p LOH, both alleles of the WT1 ARR are hypomethylated, and a
similar change is seen in premalignant nephrogenic rests (NRs). The differential
methylation in normal kidney is associated with genomic imprinting of the WT1 anti-
sense transcript, leading to monoallelic expression from the paternal allele. In WTs
and NRs, imprinting is relaxed, with biallelic expression of antisense RNA. We have
previously shown that in vitro expression of antisense RNA affects WT1 protein
levels, and so loss of imprinting of the WT1 ARR may be an important step in the
development of WT. 
Using an array-based screening technique, we have detected altered methylation of
a number of other loci in WT. One of these shows differential methylation in normal
kidney and hypomethylation in WT, like the WT1 ARR. This locus maps to chromo-
some 12q, an area frequently involved in numerical cytogenetic changes in WT. 
These results indicate that epigenetic alterations are a common early change in WT
and may play a vital part in the molecular pathogenesis of WT. 
This work was supported by the Cancer & Leukaemia in Childhood charity. 
Malik K et al 2000 Identification of differential methylation of the WT1 antisense
regulatory region and relaxation of imprinting in Wilms’ tumour. Cancer Res
60: 2356–2360 
Malik K & Brown KW 2000 Epigenetic gene deregulation in cancer. Br Cancer
83: 1583–1588 
10.2
GENOMIC IMBALANCES IN PAEDIATRIC EPENDYMOMAS; A
UNITED KINGDOM CHILDREN’S CANCER STUDY GROUP
(UKCCSG) APPROVED STUDY SA Dyer1, EJ Prebble1, EV Davison1, 
DW Ellison2, RG Grundy3, 1Regional Genetics Laboratory, Birmingham
Women’s Hospital, Edgbaston, Birmingham, B15 2TG, 2Cancer Research
Unit, University of Newcastle, Newcastle, 3Institute of Child Health, University
of Birmingham, Whittle Street, Birmingham, B4 6NH, UK 
Ependymomas are the third most common primary brain tumour of childhood
accounting for 10–15% of all tumours in this age group. Analysis of the traditional
clinico-pathological variables of histology, age and site has yielded conflicting results
and currently there are no clear prognostic factors for childhood ependymomas. Part
of the reason for this relates to our poor understanding of the biology of these tumours. 
We have initiated a large, retrospective comparative genomic hybridisation (CGH)
study of 70 formalin fixed paraffin embedded (FFPE) ependymomas. The use of
FFPE-CGH was validated in our laboratory using 15 fresh/FFPE ependymoma pairs.
Complete correlation of paired fresh/FFPE tumour CGH profiles was observed. 
To date, we have analysed 33 primary and 9 recurrent FFPE ependymal tumours
collected from 38 children. Genomic imbalances were observed in 20/33 (61%)
primary ependymomas and 8/9 (89 %) recurrent tumours. The mean number of imbal-
ances for both primary and recurrent tumours was 2.7. Whole chromosome imbal-
ances were more common in the primary tumours, whereas partial gains and losses
predominated in the recurrent tumours. The most common imbalances observed in
primary ependymomas were gain of 1q (27%), gain of 9p (24%), loss of 17p (12%)
and loss of 6q (9%). The recurrent ependymomas most frequently exhibited gain of 1q
(67%) and loss of 6q (22 %). 
CGH analysis of the remaining 28 FFPE ependymoma samples is in progress and
results from the complete series will be correlated with clinical details. Oral presentations 31
10.3
PAX3-FKHR INDUCES MORPHOLOGICAL CHANGES AND
ENHANCES CELLULAR PROLIFERATION AND INVASION IN
RHABDOMYOSARCOMA J Anderson1, A Ramsay, D Henderson, 1Unit of
Molecular Haematology, and Department of Haematology and Oncology,
2Department of Histopathology, 3Neurodevelopment Unit, Institute of Child
Health and Great Ormond Street Hospital for Children, London, UK 
Alveolar rhabdomyosarcoma (ARMS) was originally distinguished from other
subtypes of rhabdomyosarcoma on the basis of its morphological appearance. Since
the recognition of this entity, it has been shown to have a poorer prognosis and to be
consistently associated with the characteristic translocations t(2;13)(q35;q14) and
t(1;13)(p36;q14), which encode for the PAX3-FKHR and PAX7-FKHR fusion onco-
proteins respectively. We have investigated the relationship between PAX3-FKHR
expression and ARMS histogenesis by correlating their phenotype in primary tumors
and by analyzing the effects of ectopically expressed PAX3-FKHR on embryonal
rhabdomyosarcoma (ERMS) cell lines and developing myoblasts in transgenic mice. 
In a previous blinded histological review of discrepant primary tumors in which
there was PAX3-FKHR expression but ERMS histology, we found small areas of
alveolar histology in 6 out of 11 cases. This suggests that histology alone may under-
represent the association between PAX3-FKHR and ARMS, and we proceeded to
investigate this link by examining the effect of ectopic PAX3-FKHR expression on
ERMS cells. Two ERMS cell lines, RD and HX170C were stably transfected with a
PAX3-FKHR expression construct. In cloned transfectants derived from both cell
lines PAX3-FKHR expression resulted in increased proliferative rate in vitro and
promoted cell growth in the absence of added growth factors. Tumors that formed as
xenografts in immunodeficient mice were faster growing, more locally invasive and
had a denser, more pleomorphic architecture. The characteristic clefts and alveolar
spaces of ARMS however were not seen. The denser cellular architecture suggests
increased cellular adhesion. PAX3-FKHR expression by itself did not result in greater
metastatic spread. In contrast, tumors grown as xenografts from individual clones
derived from several ARMS cell lines showed all the classical morphological features
of ARMS suggesting divergence in vivo from precursor cells propagated in culture. 
Because of the possible origin of rhabdomyosarcoma cells in early development,
we chose to investigate further the role of PAX3-FKHR on migration and growth by
assessing the effect of its forced expression in developing myoblasts. We therefore
generated transgenic mice with PAX3-FKHR expression controlled by the murine
MyoD promoter. Embryos demonstrate both failure of normal myogenesis and aber-
rant migration of myoblasts, recapitulaing some of the features of ARMS. Ongoing
studies are employing tamoxifen-inducible regulatory PAX3-FKHR cellular systems
and gene array technology to identify the genes regulated in ERMS cells that are
responsible for the more malignant phenotype. 
10.4
EXPRESSION PROFILE OF ETV6, CBFA2 AND ETV6-CBFA2
IN CHILDHOOD ALL AND AML N Patel1, LK Goff2, LK Jones1, 
T Clark3, N Foot3, D Lillington3, S Hing4, K Pritchard-Jones4, V Saha1, 1ICRF
Children’s Cancer Group, 2Dept of Medical Oncology, St Bartholomew’s and
The Royal London School of Medicine and Dentistry, London EC1M 6BQ,
3Centre of Statistics in Medicine, Institute of Health Sciences, Oxford OX3
7LF, 4Dept of Paediatric Oncology, Institute of Cancer Research/Royal
Marsden NHS Trust, Surrey SM2 5PT, UK 
The transcription factors, ETV6 and CBFA2 are essential in the development of
normal haematopoiesis. In about 25% of childhood ALL, these two genes are
rearranged to form the ETV6-CBFA2 chimeric gene. This study used real-time PCR
(RQ-RTPCR) to investigate the expression pattern of ETV6, CBFA2 and ETV6-CBFA2
in three groups of patients: ETV6-CBFA2 Positive ALL (Group A), ETV6-CBFA2
Negative ALL (Group B), and AML (Group C) patients. 
Method Bone marrow samples were taken in disease (at presentation or at
relapse) and in remission states from 16 Group A, 13 Group B and 9 Group C patients.
Total RNA was extracted from mononuclear cells using the RNAzol-B method,
reverse transcribed into cDNA with M-MLV reverse transcriptase and random hexa-
mers. All samples were analysed in parallel with b2M as the internal control gene by
RQ-RTPCR. The cycle threshold (CT) value was determined from the amplification
plot for the individual gene and then subtracted from the b2M CT value to obtain differ-
ential (n nCT) expression. Thus n nCT values indicate high gene expression. 
Results CBFA2 expression was significantly increased in the disease state in all
ALL patients (P < 0.0001). The expression levels normalized with remission. This
difference in the expression was not observed in those AML, where CBFA2 expres-
sion remained unchanged with disease status. There was no obvious difference in the
ETV6 expression between disease and remission states for any groups of patients.
However, ETV6 expression was significantly elevated in the diseased state in Group
B, as compared to Group A. The three out of four patients with matched pair samples
at presentation and at relapse showed decrease in ETV6-CBFA2 expression, but this is
not statistically significant. 
Conclusion This study shows that CBFA2 is upregulated in the diseased state of
all ALL patients. Since CBFA2 is involved in acetylating chromatin, histone acetyl
transferases may have a therapeutic role in childhood ALL. The decrease in level of
ETV6-CBFA2 expression in the relapsed state, suggests that secondary events are
responsible for recurrence of disease. 
10.5
A UKCCG AND UKCCSG STUDY OF KARYOTYPE DATA
FROM PATIENTS WITH EWING’S SARCOMA TUMOURS 
P Roberts1, CA Felix1, IJ Lewis2, SA Burchill3, 1Dept Cytogenetics, 
St James’s Hospital, Leeds LS9 7TF, 2Paediatric Oncology & 3Candlelighter’s
Research Dept, St James’s, Leeds, UK 
Prognostic parameters for patients with Ewing’s sarcoma (ES) tumours include pres-
ence or absence of metastatic disease at diagnosis, tumour volume and site. Over 85%
demonstrate a t(11;22) translocation with a further 5% showing a variant of this,
creating a gene fusion between EWS at 22q12 and an ETS family gene on the partner
chromosome. A wide variety of fusion transcript types have been described, the nature
of which has a bearing on prognosis. However, some patients with apparently
favourable clinical and molecular genetic features still relapse and die, suggesting
other factors may contribute to disease prognosis and progression. 
80% of ES patients demonstrate additional secondary chromosome changes at
diagnosis, although few studies have assessed the possible clinical importance of
these. Our UKCCG and UKCCSG study involves the collection of karyotype data
from UK patients aged up to 30 years with ES tumours in order to assess the nature
and possible prognostic effect of any consistent secondary chromosome changes. 
We have received karyotype data from 105 chromosomally abnormal individuals
from 12 UK centres with ES tumours, the largest series to date. 76% demonstrated
secondary chromosome changes at diagnosis, typically simple trisomies, the most
frequent of which were trisomy 8 (35%) and trisomy 12 (17%). Besides 1p deletion
and an unbalanced t(1;16) translocation, there have been few documented reports of
secondary structural chromosome imbalance. Our studies revealed 1p36 deletion in
9% and 16q loss in 21%, as well as several previously undocumented deletions – i.e.
3q (10%), 9p (9%), 11q (6%) and 17p (7%). 
Initial indications of the data suggest that individuals with complex karyotypes at
diagnosis fare worse than those with simple changes, irrespective of metastases. We
now intend to assess whether any of the recurrent chromosome abnormalities have
prognostic implications, particularly in those individuals where the number of these is
relatively low. We hope that further evaluation of these chromosome changes may
shed more light on the underlying molecular genetic changes and their contribution to
disease progression and survival. We hope to complete the study by early 2002. 
10.6
GROWTH FACTOR PROFILE OF TUMOURS OF THE
EWING’S SARCOMA FAMILY EXAMINED USING CDNA
ARRAYS J Withey and SA Burchill, Candlelighter’s Children’s Cancer
Research Laboratory, ICRF Clinical Centre, St James’s University Hospital,
Leeds LS9 7TF, UK 
Growth factors and their receptors are important in normal cell growth, activating
signalling pathways which can stimulate or inhibit cell division, differentiation and
migration. Aberrant expression of these proteins can contribute to tumorigenesis by
modulating tumour cell attachment, growth and angiogenesis. 
We have previously shown that Ewing’s Sarcoma (ES) cell lines can maintain their
cell number under serum-free conditions and that ES conditioned media provides
these cells with a survival advantage compared to normal media (1). The aims of this
work were to determine 1) what growth factors/receptors are expressed by these cell
lines and tumours which might mediate such an advantage and 2) if the expression of
any of these growth factors may be prognostically significant. 
Total RNA extracted from 6 ES cell lines and 2 tumour samples taken at diagnosis
was labelled and hybridised to cDNA cytokine/receptor arrays (Clontech). Results
were analysed using AtlasImage 1.01 (Clontech) which identified seventeen growth
factor or receptor genes highly expressed in more than half of the cell lines and both
tumours. Four were present in all samples, thymosin beta 10, pleiotrophin,
smoothened and p75. The expression of these growth factors was confirmed by
reverse transcriptase-polymerase chain reaction (RT-PCR) and Southern blotting or
sequencing. Two of the growth factors, tymosin beta 10 and pleiotrophin were
explored in greater detail. 
Expression of the growth factor pleiotrophin was confirmed at the protein level by
immunohistochemistry in tumour sections. The presence of its receptor, syndecan-1,
was also identified by RT-PCR and immunohistochemistry. As pleiotrophin is a
secreted growth factor, heparin affinity chromatography was used to concentrate
conditioned media from ES cell lines and determine whether this growth factor was
secreted by the cells. 
No antibodies are currently available commercially to the second growth factor,
thymosin beta 10. Antibodies were raised in rabbits to the carboxy terminal of this
peptide and also isolated from a phage library (NISSIM, MRC) by selecting against
the same peptide. These antibodies were used in immunohistochemistry to explore the
prognostic significance of thymosin beta 10 in ES. 
In summary we have identified 2 growth factors not previously described in ES
which may be useful as novel prognostic indicators and/or targets for therapy. 
1. Withey J., Burchill S.A. 2000 Br J Cancer 83 (Supp 1) 33 32 Oral presentations
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BASIC FIBROBLAST GROWTH FACTOR (BFGF)-INDUCED
CELL DEATH IN EWING’S SARCOMA IS THROUGH A
CASPASE-DEPENDENT AND P53-INDEPENDENT MECHANISM
Westwood G, Burchill SA, Candlelighter’s Children’s Cancer Research
Laboratory, St James’s University Hospital, Leeds LS9 7TF, UK 
Basic fibroblast growth factor (bFGF) is mitogenic for a number of different cell types
and has been implicated in the development and growth of many cancers. However,
we have recently shown that bGFG arrests ESFT cells at the G1 checkpoint and
induces cell death (Sturla et al, 2000). The aim of this study was to identify the mech-
anism of bFGF-induced cell death in ESFT cells. Using a general caspase inhibitor 
(Z-VAD-FMK), caspase activity was assessed using the CaspaTagTM flourescein
(FAM-VAD-FMK) caspase activity kit (Intergen) as well as the trypan blue exclusion
assay. Initiator and effector caspases involved in bFGF-induced cell death were iden-
tified using the caspase substrate set III (Calbiochem) and western blotting for
cleavage of poly (ADP-ribose) polymerase (PARP). Immunohistochemistry and
western blotting measured expression of bcl-2 family members. Mitochondrial trans-
membrane potential was analysed using tetramethylrhodamine ethyl ester percholate
(TMRE) labelling and FACs analysis; cytochrome c release was characterised by
subcellular fractionation and western blot. p53 gene status in the ESFT cell lines was
analysed by single strand conformational polymorphism (SSCP) and sequencing.
Caspase activity was first detected 36 h post-bFGF (10 ng/ml) treatment. The caspase
inhibitor Z-VAD-FMK (10 mM) significantly protected TTC-466 and TC-32 cells
from bFGF-induced cell death (p<0.01). The initiator (caspase-2, -8, -10) and effector
(caspase-3, -6, -7) caspases were activated in the TC-32 and TTC-466 cells after treat-
ment with bFGF (10 ng/ml) treatment. Expression of bcl-2 was down-regulated and
bax up-regulated in TC-32 and TTC-466 cells treated with bFGF (10 ng/ml) for 48 h.
Furthermore, high basal expression levels of bcl-2 was observed in the bFGF-unre-
sponsive ESFT cell line (A673), with both bFGF-responsive (TC32, TT466) and
unresponsive (A673) ESFT cell lines having mutated p53. In conclusion, bFGF-
induced cell death in ESFT is through a caspase-dependent and p53-independent
mechanism. Furthermore, bcl-2 may protect ESFT from bFGF-induced cell death. 
Sturla L et al. 2000, Cancer Res 60: 6160
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DAMAGE-INDUCED BAX N-TERMINAL CHANGE AND
TRANSLOCATION TO MITOCHONDRIA OCCUR
REGARDLESS OF CELL FATE G Makin, A Thistlethwaite, B Corfe, 
G Griffiths, J Hickman1, C Dive, CRC Molecular and Cellular Pharmacology
Group, School of Biological Sciences, University of Manchester, Manchester
M13 9PT, UK, 1Institut de Recherches Servier, Suresnes, 92150, Paris,
France 
Resistance to chemotherapy is the major obstacle to the successful treatment of
neuroblastoma. A model system for the investigation of drug-resistance in vitro is
described, exploiting two NB cell lines, SH-EP1 and SH-SY5Y, derived from the
same parental background. These subclones show no difference in their sensitivity to
the DNA damaging agent cisplatin, but have very different responses to the micro-
tubule stabilising agent paclitaxel; SH-EP1 cells are sensitive, whilst SH-SY5Y cells
are resistant. The protein product of the tumour suppressor gene p53 is stabilised to
the same extent in SH-SY5Y cells following exposure to cisplatin, which readily
engage apoptosis, as in those exposed to paclitaxel, which do not. Stabilised p53 is
active in SH-SY5Y cells following paclitaxel exposure as reflected by the transcrip-
tional upregulation of the cyclin dependant kinase inhibitor, p21WAF-1, a downstream
effector of p53, after both drug treatments. The pro-apoptotic Bcl-2 family protein
Bax is latent in healthy cells and requires activation by drug-damage signals.
Exposure of an epitope in the N-terminus of Bax was observed in both NB cell lines
following both types of drug induced damage. This N-terminal exposure occurred to
the same extent in settings of drug resistance as in those of drug sensitivity. The expo-
sure of the N-terminus of Bax occurred in the cytosol, and was followed by the
translocation of Bax to the mitochondria, again irrespective of cell fate. The exposure
of the N-terminus of Bax was also observed following detachment of NB cells into
suspension. Thus the N-terminal changes in Bax represent a reversible response to
disparate types of damage, and do not commit the cell to death. A model for the acti-
vation of Bax by drug-induced damage in NB cells is suggested that must require a
second signal, after N-terminal epitope exposure and mitochondrial translocation,
which is needed to commit the cell to apoptosis. This damage-induced second signal
is suggested to be abrogated in SH-SY5Y cells after treatment with paclitaxel. Lack of
the full activation of Bax may represent a novel method of drug resistance in NB cells.